

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/87, 15/62, A61K 38/16, C12N 5/10</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/13599</b> <b>(43) International Publication Date:</b> 9 May 1996 (09.05.96)
<b>(21) International Application Number:</b> PCT/EP95/04270 <b>(22) International Filing Date:</b> 31 October 1995 (31.10.95)  <b>(30) Priority Data:</b> 94810627.3 1 November 1994 (01.11.94) EP <b>(34) Countries for which the regional or international application was filed:</b> GB et al.  <b>(71)(72) Applicant and Inventor:</b> WELS, Winfried [DE/DE]; Glimpenheimer Strasse 55, D-79312 Emmendingen (DE).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> FOMINAYA, Jesus [ES/CH]; Maulbeerstrasse 71, CH-4058 Basel (CH).  <b>(74) Agent:</b> SCHREINER, Siegfried; Boehringer Mannheim GmbH, Werk Penzberg/Abt. GE-TB, Postfach 11 52, D-82372 Penzberg (DE).		<b>(81) Designated States:</b> AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> NUCLEIC ACID TRANSFER SYSTEM  <b>(57) Abstract</b> <p>The invention pertains to a nucleic acid transfer system including a translocation domain of toxins, especially of diphtheria toxin suitable for targeting a nucleic acid, e.g. a gene, to a specific cell, and obtaining expression of said nucleic acid. The nucleic acid transfer system of the invention comprises a multidomain protein component and a nucleic acid component. Furthermore, the present invention relates to the multidomain protein, a nucleic acid encoding said protein, suitable amplification and expression systems for said nucleic acid, and processes for the preparation and uses of the above subject matters.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### Nucleic acid transfer system

The invention pertains to a nucleic acid transfer system suitable for targeting a nucleic acid, e.g. a gene, to a specific cell, and obtaining expression of said nucleic acid. The nucleic acid transfer system of the invention comprises a multidomain protein component and a nucleic acid component. Furthermore, the present invention relates to the multidomain protein, a nucleic acid encoding said protein, suitable amplification and expression systems for said nucleic acid, and processes for the preparation and uses of the above subject matters.

Gene transfer to eukaryotic cells may be accomplished using viral vectors, such as recombinant adenoviruses, or non-viral gene transfer vectors. Owing to several disadvantages, .g. constraints in the size of the DNA to be delivered, incapability of transducing terminally differentiated cells, potential safety hazards and insufficient targetability, such viral DNA transfer systems seem to be of limited use in gene therapy strategies. As an alternative to viral systems, ligand-mediated approaches via molecular conjugate vectors have been developed. Such molecular conjugate vectors comprise the DNA molecule to be transferred and a target cell-specific ligand which is chemically coupled to a polycation, particularly a polyamine (for review, see e.g. Michael & Curiel, *Gene Therapy* 1: 223, 1994). The polycation binds to the DNA through electrostatic forces, thus acting to tie up the ligand with the gene to be delivered. For example, human transferrin or chicken conalbumin were covalently linked to poly-L-lysine or protamine through a disulfide linkage. Complexes of protein-polycation-conjugate and a bacterial plasmid containing a luciferase encoding gene were supplied to eukaryotic cells, resulting in expression of the luciferase gene (Wagner et al., *Proc. Natl. Acad. Sci. USA* 87: 3410, 1990). To achieve higher levels of gene expression, adenovirus particles were chemically coupled to the complex (see e.g. Curiel et al., *Proc. Natl. Acad. Sci. USA* 88: 8850, 1991; Christiano et al., *Proc. Natl. Acad. Sci. USA* 90: 11548, 1993). However, molecular conjugate vectors also have limitations, including large size, inhomogeneity, lack of specificity pertaining to the binding of the DNA component, and non-specific binding due to electrostatic interactions between the polycation and the cell membrane, which may at least partially neutralize the targetability imposed by the ligand.

Thus there is still a need for a simple, efficient nucleic acid transfer system which allows e.g. the target cell-specific introduction of nucleic acids to be expressed, but lacks the disadvantages of the prior art concepts.

It is the object of the present invention to provide such a system. The nucleic acid transfer system according to the invention is characterized by the following two components:

- 1) a multi-domain protein comprising several functional domains including a nucleic acid binding domain
- 2) an effector nucleic acid, particularly a DNA, comprising the nucleic acid, e.g. the gene, to be delivered to and expressed in a selected target cell, and a cognate structure recognizable by the nucleic acid binding domain of the protein.

The multi-domain protein component combines in a single molecule a target cell recognition function, also referred to as ligand domain, an endosome escape function and a nucleic acid binding function, particularly a DNA binding function. Such a protein does not occur in nature. The nucleic acid binding function serves to mediate the specific, high affinity and non-covalent interaction of the protein component with the effector nucleic acid component. Unlike the above described molecular conjugate vector of the prior art, the protein/nucleic acid complex of the present invention is formed by specific interaction of the nucleic acid binding domain with its cognate structure on the effector nucleic acid. Advantageously, the binding affinity of the proteinaceous nucleic acid binding domain for its cognate structure on the effector nucleic acid surpasses the affinity of the proteinaceous target cell recognition function for its cognate molecular structure on the target cell. Within the nucleic acid transfer system of the present invention the effector nucleic acid component may be e.g. a complete or partial plasmid carrying the nucleic acid to be expressed in the target cell. The nucleic acid delivery system of the invention is designed such that the rate of nucleic acid transfer is optimized.

Advantageously, the present system makes use of physiological target-cell inherent mechanisms of macromolecular transport involving endosomes, particularly receptor-mediated endocytosis. The protein/nucleic acid complex according to the invention is targetable in that it may be efficiently internalized only by a predetermined cell-type or cell population carrying a molecular structure, e.g. a receptor, which specifically interacts with the target cell recognition function of said complex. After entering the cell, the protein/nucleic acid complex of the



invention becomes localized in endosomes from where it is released into the cytoplasm. Owing to the selective internalization of the protein/nucleic acid complex, expression of the particular nucleic acid(s) to be delivered by the complex of the invention occurs in a way that distinguishes (transfected) target cells from (non-transfected) non-target cells, e.g. expression is essentially confined to the predetermined target cell. The nucleic acid to be transported to and expressed in the target cell may be therapeutically active or encode a therapeutically active product, e.g. tumor cells may be transfected to introduce a gene coding for a therapeutically active protein.

More specifically, the present invention provides a two-component system for the target cell-specific delivery and uptake of a non-covalently linked protein/nucleic acid complex leading to the expression in said target cells of one or more nucleic acids comprised by the transferred effector nucleic acid. Preferentially, such system of the invention essentially consists of a protein/nucleic acid complex containing two components:

- a polypeptide chain containing several different functional domains of eukaryotic, prokaryotic or synthetic origin, and
- an effector nucleic acid.

Advantageously, the protein/nucleic acid complex is sufficiently stable in physiological fluids to enable its application in vivo. The complex of the invention is a molecular complex, whose stoichiometry is essentially determined by the number of cognate structures of the protein nucleic acid binding domain on the effector nucleic acid. For example, the cognate structure of the yeast GAL4 binding domain is thought to bind a protein dimer. Accordingly, the ratio of multidomain protein to effector nucleic acid in the complex of the invention is 2:1 by using one nucleic acid binding domain. However, it is preferred to use nucleic acids which contain multiple sequences (preferably 2-8 which recognize the nucleic acid binding domain).

Successful transfer and expression of the desired nucleic acid depends on the specific interaction of the protein/nucleic acid complex with the target cell and on the efficient transfer of the nucleic acid of interest across systemic or subcellular barriers. To examine whether the complex of the invention is transported into or within the target cell, the complex may be suitably labeled and its accumulation in and in cells determined, e.g. by fluorescence imaging. For example, the complex may be fluorescence-labeled and its cellular localization be visualized, e.g. by video-enhanced microscopy and quantitative confocal laser scanning. Other

assays suitable for determining the functionality of the nucleic acid transfer system of the invention, such as an assay for the expression of a delivered reporter gene, are described in the Examples. Further assays are known in the art and evident to the skilled person.

The nucleic acid delivery system of the invention provides for e.g. for efficient gene transfer in that it enables e.g. transit of said gene through the eukaryotic cell plasma membrane, transport to the nucleus, nuclear entry and functional maintenance within the nucleus. Persistence of gene expression can be achieved either by stable chromosomal integration of heterologous DNA or by maintenance of an extrachromosomal replicon. Preferably, the system of the invention lacks sequences which raise safety issues, e.g. complete viral genomes capable of autonomous replication or containing viral oncogenes. A system of the present invention may be designed such as to provide a safe, non-toxic and efficient in vivo nucleic acid transfer system.

In a further aspect, the present invention relates to the above captioned multidomain protein which is capable of specifically binding to an effector nucleic acid as defined according to the invention by its nucleic acid binding domain and mediating the introduction of said effector nucleic acid into a target cell.

The multidomain protein of the invention which may comprise one or more polypeptide chains is produced using chemical and/or recombinant methods known in the art. Preferably, said protein is a recombinant single chain protein.

The functional domains characterizing the protein of the invention are:

- (1) a target cell-specific binding or ligand domain recognizing a cellular surface structure, e.g. an antigenic structure, a receptor protein or other surface protein, which mediates internalization of a bound ligand.
- (2) a translocation domain facilitating the escape of the effector nucleic acid from endocytic vesicles after internalization of said complex into target cells, e.g. via receptor mediated endocytosis,
- (3) a nucleic acid binding domain recognizing and binding with high affinity to a defined structure of the effector nucleic acid component, e.g. to a specific DNA sequence on a suitable eukaryotic expression plasmid or a suitable linear DNA fragment, and, optionally,

- 5 -

- (4) an endoplasmic reticulum retention signal affecting the intracellular routing of the internalized protein/nucleic acid complex, and
- (5) a nuclear localisation signal.

There is particularly preferred

- a multidomain protein comprising, as functional domains, a target cell-specific binding domain, a translocation domain and a nucleic acid binding domain, characterized in that the translocation domain is derivable from diphtheria toxin and does not include that part of said toxin molecule which confers to the cytotoxic effect of the molecule; or
- a multidomain protein comprising, as functional domains, a target cell-specific binding domain, a translocation domain and a nucleic acid binding domain, characterized in that the translocation domain is derivable from bacterial toxins and the target cell-specific binding domain which recognizes a cell surface receptor selected from the group of the EGF receptor-related family of growth factor receptors; or
- a multidomain protein comprising, as functional domains, a target cell-specific binding domain, a translocation domain and a nucleic acid binding domain, characterized in that the translocation domain is derivable from a bacterial toxin and the target cell-specific binding domain recognizes a cell surface receptor on the effector cells of the immune system.

Within the multidomain protein of the invention the above captioned independent components function in a concerted manner to achieve targeted, highly efficient internalization of a nucleic acid of interest provided by an effector nucleic acid, e.g. by an eukaryotic expression plasmid, to a selected cell or cell population, thereby contributing to the successful expression of said nucleic acid of interest. The arrangement of the component domains is chosen in accordance with the functionality of the individual domains. In an embodiment of the invention using a translocation domain derivable from a toxin, e.g., *P. aeruginosa* exotoxin A or diphtheria toxin, the arrangement of domains in N- to C-terminal order may be as follows: ligand binding domain - translocation domain - nucleic acid binding domain - (optionally) endoplasmic reticulum retention signal.

The protein of the invention may comprise one or more functional domains serving the same function. For example, to facilitate binding of the effector nucleic acid, the protein may

comprise one or more nucleic acid binding domains recognizing the same or different cognate structures on the effector nucleic acid. The protein may comprise one or more ligand domains having the same or different specificities. As evident from the Examples, one copy of each functional domain is sufficient for a multidomain protein of the invention to perform its above captioned function.

In addition to these functional domains the protein component may comprise one or more, particularly one, two, three or four further amino acid sequences. For example, such inserts, preferably consisting of genetically encoded amino acids, may advantageously be incorporated into the multidomain protein of the invention to serve as a linker or spacer between the above identified functional domains. Thus the insert connects the C-terminal amino acid of one functional domain with the N-terminal amino acid of another functional domain. A suitable insert may not impair the favorable properties of the multidomain protein as such. For example, a linker may be a peptide consisting of about 1 to about 20 amino acids. Exemplary inserts include peptides having the amino acid sequences GluLysLeuGluSerSerAspTyrLysAspGluLeu (SEQ ID NO:40), HisHis, HisHisHisHis (SEQ ID NO:41), SerSerAspTyrLysAspGluLeu (SEQ ID NO:42), and other sequences evident from the Examples. Additional amino acids may also be incorporated at the N-terminus of the multidomain protein. Exemplary amino acid sequences include the FLAG epitope and are identified for SEQ ID NOs. 1, 3 and 5 in the Examples.

The target cell-specific binding domain is chosen so as to achieve targetability and cellular internalization of the protein/nucleic acid complex of the invention. It enables the specific interaction of the protein/nucleic acid complex of the invention with a selected structure on the target cell which structure mediates cellular internalization by, for example, the process of endocytosis. Preferably, said domain attaches to the target cells in a fashion compatible with a ligand receptor union, thereby mediating entry of the protein/nucleic acid complex into the cell. In the protein/nucleic acid complex of the invention said ligand domain maintains the ability of the "parent protein" it is derivable from to bind to the cognate structure, e.g. the receptor, in such a way that endocytosis of said complex is accomplished. Preferred is a target cell-specific binding domain, recognition and binding of which by its appropriate cell surface receptor allows cellular internalization of the protein/nucleic acid complex via receptor-mediated endocytosis.

A precondition for a proteinaceous molecule to be suitable as a binding domain in the multidomain protein of the invention is that it binds to a surface-structure on specific target

cells, which surface structure is capable of mediating internalization of its ligand into the target cell via an endocytotic pathway and that these properties are not substantially impaired for the multidomain protein of the invention.

A target cell-specific binding domain recognizing a cell surface structure, such as a receptor protein or a surface antigen on the target cell, is e.g. derivable from a ligand of a cell specific receptor, such as a Fc receptor, transferrin receptor, EGF receptor, asialoglycoprotein receptor, cytokine receptor, such as a lymphokine receptor, a T cell specific receptor, e.g. CD 45, CD4 or CD8, the CD 3 receptor complex, TNF receptor, CD 25, erbB-2, an adhesion molecule, such as NCAM or ICAM, and mucine. Suitable ligands include antibodies specific for said receptor or antigen. Further molecules suitable as ligand domain in the multidomain protein of the invention include factors and growth factors, e.g. tumor necrosis factor, e.g. TNF- $\alpha$ , human growth factor, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF), such as TGF $\alpha$  or TGF $\beta$ , nerve growth factor, insulin-like growth factor, a peptide hormone, e.g. glucagon, growth hormone, prolactin, or thyroid hormone, a cytokine, such as interleukin, e.g. IL-2 or IL-4, interferon, e.g. IFN- $\gamma$ , or fragments or mutants of such proteins with the provision that such fragments and mutants fulfill the above requirements for a ligand domain. For example, suitable antibody fragments include Fab fragments, Fv constructs, e.g. single chain Fv constructs (scFv) or an Fv construct involving a disulfide bridge, and the heavy chain variable domain. The ligand domain may be of natural or synthetic origin and will vary with the particular type of target cell.

Especially preferred, as target cell-specific binding domains, are domains which recognize (bind to) a cell surface receptor selected from the groups of the EGF-receptor related family of growth factor receptors. Such cell surface receptors are, e.g., TGF $\alpha$  receptor, EGF receptor, erbB2, erbB3 or erbB4 (Pelles, E., and Yarden, Y., Bioassays 15 (1993) 815-824). Preferred as binding domains in the transfer system are growth factors like heregulin, EGF, betacellulin, TGF- $\alpha$ , amphiregulin or heparin binding EGF as well as antibodies against erbB2, erbB3, erbB4 or EGF receptor.

Further preferred are cell surface structures of effector cells of the immune system, especially of T cells. Such structures are, e.g., IL-2 receptor, CD4 or CD8.

Whether in the multidomain protein of the invention the ligand domain is capable of recognizing and binding its cognate structure may be determined according to methods known in the art. For example, a competition assay may be employed to determine whether entry of

the protein/DNA complex of the invention is specifically mediated by the target cell-specific binding domain. For example, if excess of the free ligand serving as ligand domain, or of the free protein the target cell-specific binding domain is derivable from, competes with binding, endocytosis and nuclear localization of the suitably labeled complex, binding and entry of the complex into the cell is specifically mediated by said target cognate moiety of the complex.

A preferred ligand domain is e.g. a single chain antigen binding domain of an antibody, e.g. a domain derivable from the heavy chain of an antibody, and particularly a single chain recombinant antibody (scFv). Preferentially, the antigen binding domain is a single-chain recombinant antibody comprising the light chain variable domain ( $V_L$ ) bridged to the heavy chain variable domain ( $V_H$ ) via a flexible linker (spacer), preferably a peptide. Advantageously, the peptide consists of about 10 to about 30 amino acids, particularly naturally occurring amino acids, e.g. about 15 naturally occurring amino acids. Preferred is a peptide consisting of amino acids selected from L-glycine and L-serine, in particular the 15 amino acid peptide consisting of three repetitive units of Gly-Gly-Gly-Gly-Ser (SEQ ID NO:43). Advantageous is a single-chain antibody wherein  $V_H$  is located at the N-terminus of the recombinant antibody. The antigen binding domain may be derivable from a monoclonal antibody, e.g. a monoclonal antibody directed against and specific for a suitable antigen on a tumor cell.

A suitable antigen is an antigen with enhanced or specific expression on the surface of a tumor cell as compared to a normal cell, e.g. an antigen evolving from consistent genetic alterations in tumor cells. Examples of suitable antigens include ductal-epithelial mucine, gp 36, TAG-72, growth factor receptors and glycosphingolipids and other carbohydrate antigens preferentially expressed on tumor cells. Ductal-epithelial mucine is enhancedly expressed on breast, ovarian and pancreas carcinoma cells and is recognized e.g. by monoclonal antibody SM3 (Zotter et al., Cancer Rev. 11, 55-101 (1988)). The glycoprotein gp 36 is found on the surface of human leukemia and lymphoma cells. An exemplary antibody recognizing said antigen is SN 10. TAG-72 is a pancarcinoma antigen recognized by monoclonal antibody CC49 (Longenecker, Sem. Cancer Biol. 2, 355-356). Growth factor receptors are e.g. the human epidermal growth factor (EGF) receptor (Khazaie et al., Cancer and Metastasis Rev. 12, 255-274 (1993)) and HER2, also referred to as erbB-2 or gp 185 (A. Ullrich and J. Schlessinger, Cell 61, 203-212 (1990)). The erbB-2 receptor is a transmembrane molecule which is overexpressed in a high percentage of human carcinomas (N.E. Hynes, Sem. in Cancer Biol. 4, 19-26 (1993)). Expression of erbB-2 in normal adult tissue is low. This difference in expression identifies the erbB-2 receptor as "tumor enhanced".

Preferably, the antigen binding domain is obtainable from a monoclonal antibody produced by immunization with viable human tumor cells presenting the antigen in its native form. In a preferred embodiment of the invention, the recognition part of the multidomain protein of the invention specifically binds to an antigenic determinant on the extracellular domain of a growth factor receptor, particularly HER 2. Monoclonal antibodies directed to the HER2 growth factor receptor are known and are described, for example, by S.J.McKenzie et al., *Oncogene* 4, 543-548 (1990), R.M. Hudziak et al., *Molecular and Cellular Biology* 9, 1165-1172 (1989), International Patent Application WO 89/06692 and Japanese Patent Application Kokai 02-150 293. Monoclonal antibodies raised against viable human tumor cells presenting HER2 in its native form, such as SKBR3 cells, are described, for example, in European patent application EP-A-502 812 which is enclosed herein by reference, and include antibodies FRP5, FSP16, FSP77 and FWP51 (ECACC 90112115, 90112116, 90112117 and 90112118).

Most preferred is the single chain antibody scFv(FRP5) as described in the Examples and SEQ ID NOs. 1 and 2.

Further preferred as a ligand domain is a cognate structure binding fragment derivable from a cytokine, particularly TGF- $\alpha$  or interleukin-2. Particularly preferred is a TGF- $\alpha$  fragment having the sequence set forth in SEQ ID No. 4, which sequence extends from the amino acid at position 13 (Val) to the amino acid at position 62 (Ala). Equally preferred is a IL-2 fragment having the sequence set forth in SEQ ID No. 6, which sequence extends from the amino acid at position 18 (Ala) to the amino acid at position 150 (Thr).

Particularly preferred are the ligand domains as employed in the Examples. The amino acid sequences of the domains designated sc(Fv)FRP5, TGF- $\alpha$  and IL-2 are identified for SEQ. ID. Nos. 1, 3 and 5, respectively.

Within the present invention a target cell is a cell that via a specific cell surface structure is capable of selectively binding the target cell-specific binding domain comprised in the protein/nucleic complex of the invention. The cell surface structure may be a protein, a carbohydrate, a lipid or combination thereof. Advantageously, such target cell possesses a unique receptor which - by binding to the target cell-specific binding domain of the multidomain protein of the invention - mediates the efficient internalization of substantially the protein/nucleic acid complex into the target cell.

Within the multidomain protein of the invention the translocation domain functions to enhance nucleic acid escape from the cellular vesicle system and thus to augment nucleic acid transfer by this route. This domain serves to reduce or avoid lysosomal degradation after internalization of the protein/nucleic acid complex into the target cell. WO 94/04696 describes a nucleic acid transfer system wherein, as a translocation domain and a receptor binding domain, the cognate domains of P. exotoxin A are used. However, the transfection efficiency and specificity of such transfer systems are very low. The invention, therefore, provides an improved nucleic acid transfer system exhibiting a high transfection efficiency and specificity. Suitable translocation domains are derivable from toxins, particularly bacterial toxins, such as exotoxin A, Colicin A, d-endotoxin, diphtheria toxin, Bacillus anthrax toxin, Cholera toxin, Pertussis toxin, E.coli toxins, Shigatoxin or a Shiga-like toxin. The translocation domain does not include that part of the parent toxin molecule which confers the cytotoxic effect of the molecule. Advantageously, the translocation domain of the recombinant protein of the invention is derivable or essentially derivable from that very part of the parent toxin which mediates internalization of the toxin into the cell, e.g. amino acids 193 or 196 to 378 or 384 of diphtheria toxin. Therefore, the part of the toxin used in the nucleic acid transfer system according to the invention does not contain a cell binding domain of a toxin.

The nucleic acid binding domain enables the specific binding of the protein component of the nucleic acid transfer system of the invention to the effector nucleic acid component of said complex. The high affinity interaction of the nucleic acid binding domain with the corresponding cognate structure on the effector nucleic acid links the cell recognition part to the expression effector part. The nucleic acid binding domain may be a RNA binding domain, or preferentially, a DNA binding domain, e.g. the DNA binding domain of a transcription factor, particularly a yeast or human transcription factor. Preferred is a GAL4 derivable domain, mediating the selective binding of the protein of the invention to the DNA sequence CGGAGGACAGTCCTCCG (SEQ ID NO:44). According to Cavey et al. (J. Mol. Biol. 209: 423, 1989) GAL4 amino acids 1 to 147 exhibit a 50 % saturation binding to the GAL4 recognition sequence at  $2 \times 10^{-11}$  M. Most preferably, the DNA binding domain of the protein of the invention consists of GAL4 amino acids 2 to 147 and has the amino acid sequence as identified for SEQ ID NO. 1 (see Example 10). A DNA binding domain may bind to a single-stranded, or preferably, to a double-stranded DNA on the effector nucleic acid.

An endoplasmic reticulum retention signal functions to affect the intracellular routing of the internalized protein/nucleic acid complex of the invention. A suitable endoplasmic retention signal may be a mammalian endoplasmic reticulum retention signal, e.g. the signal having the



amino acid sequence LysAspGluLeu (SEQ ID NO:45), i.e. the KDEL signal identified for SEQ ID NOs. 1, 3 and 5, or a functionally equivalent amino acid sequence derivable from a bacterial toxin, e.g. REDLK (SEQ ID NO:46) (single amino acid code, from ETA) or from yeast (HDEL (SEQ ID NO:47), single amino acid code).

A preferred recombinant protein of the invention comprises in e.g. as a ligand domain a single-chain antibody domain specific for the human erbB-2 receptor protein, a suitable TTF-a derivable fragment, or an IL-2 derivable fragment, a translocation domain derivable from Pseudomonas exotoxin A or diphtheria toxin, a DNA binding domain derivable from the yeast GAL4 transcription factor and a mammalian endoplasmic reticulum retention signal KDEL. Particularly preferred are the multi-domain proteins comprising the following sequences: amino acids 18 to 530 as set forth in SEQ ID No. 2, amino acids 13 to 342 as set forth in SEQ ID No. 4, or amino acids 18 to 421 in SEQ ID No. 6.

In addition to the above identified functional domains a recombinant protein of the invention may also include a signal peptide, e.g. the E. coli OmpA signal sequence having the amino acid sequence MetLysLysThrAlaIleAlaIleAlaValAlaLeuAlaGlyPheAlaThrValAlaGlnAla (SEQ ID NO:48).

The present invention also relates to a nucleic acid, i.e. a RNA or, particularly, a DNA, encoding the above described multidomain protein of the invention, or a fragment of such a nucleic acid. By definition, such a DNA comprises a coding single stranded DNA, a double stranded DNA of said coding DNA and complementary DNA thereto, or this complementary (single stranded) DNA itself. Exemplary nucleic acids encoding a protein of the invention are represented in SEQ ID NOs. 1, 3 and 5. A DNA encoding the protein designated TGFa-deltaETA-deltaGAL4 is obtainable from E. coli XL1Blue/pWF47-TGF which has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg 1b, D-38124 Braunschweig, under accession number 9513 on October 24, 1994.

Preferred are nucleic acids having substantially the same nucleotide sequence as the coding sequences set forth in SEQ ID Nos. 1, 3 and 5, respectively, or novel fragments thereof. As used herein, nucleotide sequences which are substantially the same share at least about 90 % sequence identity.

Exemplary nucleic acids can alternatively be characterized as those nucleic acids which encode a multidomain protein of the invention and hybridize to any of the DNA sequences set forth in SEQ ID Nos. 1, 3 and 5. Preferred are such sequences which hybridize under high stringency conditions to the above mentioned DNAs.

Stringency of hybridization refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature ( $T_m$ ) of the hybrid which decreases approximately 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of higher stringency, followed by washes of varying stringency. The person skilled in the art is readily able to choose suitable hybridization conditions.

Given the guidance provided herein, the nucleic acids of the invention are obtainable according to methods well known in the art. For example, a DNA of the invention is obtainable by chemical synthesis, using polymerase chain reaction (PCR) or by screening a library expressing a protein of interest, e.g. a ligand domain or a parent protein the ligand domain is derivable from, at a detectable level. Suitable libraries are commercially available or can be prepared e.g. from cell lines, tissue samples, and the like. After screening the library, positive clones are identified by detecting a hybridization signal.

Chemical methods for synthesis of a nucleic acid of interest are known in the art and include triester, phosphite, phosphoramidite and H-phosphonate methods, PCR and other autoprimer methods as well as oligonucleotide synthesis on solid supports. These methods may be used if the entire nucleic acid sequence of the nucleic acid is known, or the sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

An alternative means to isolate a DNA coding for an above mentioned functional domain is to use PCR technology as described e.g. in section 14 of Sambrook et al., 1989. This method requires the use of oligonucleotide probes that will hybridize to the nucleic acid of interest.

As used herein, a probe is e.g. a single-stranded DNA or RNA that has a sequence of nucleotides that includes at least about 20 contiguous bases that are the same as (or the

complement of) any 20 or more contiguous bases of the nucleic acid of interest. The nucleic acid sequences selected as probes should be of sufficient length and sufficiently unambiguous so that false positive results are minimized. The nucleotide sequences are usually based on conserved or highly homologous nucleotide sequences or regions of the protein of interest. The nucleic acids used as probes may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is not known.

Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode ligand binding sites, and the like. Preferably, nucleic acid probes are labelled with suitable label means for ready detection upon hybridization. For example, a suitable label means is a radiolabel. The preferred method of labelling a DNA fragment is by incorporating  $^{32}\text{P}$ -labelled  $\alpha$ -dATP with the Klenow fragment of DNA polymerase in a random priming reaction, as is well known in the art. Oligonucleotides are usually end-labelled with  $^{32}\text{P}$ -labelled  $\gamma$ -ATP and polynucleotide kinase. However, other methods (e.g. non-radioactive) may also be used to label the fragment or oligonucleotide, including e.g. enzyme labelling and biotinylation.

A nucleic acid of the invention can be readily modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof. Such mutants can be used e.g. to produce a multifunctional mutant protein comprising one or more functional domains that have an amino acid sequence differing from the sequences as found in nature. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation must not place sequences out of reading frames and preferably will not create complementary regions that could hybridize to produce secondary mRNA structure such as loops or hairpins.

The DNA encoding a multidomain protein of the invention may be incorporated into vectors for further manipulation. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles are well within the skill of the artisan. Many vectors are available, and selection of an appropriate vector will depend on the intended use of the vector, i.e. whether it is to be used for DNA amplification or for DNA expression, the size of the DNA to be inserted into the vector, and the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector components

generally include, but are not limited to, one or more of the following: an origin of replication, one or more marker genes, an enhancer element, a promoter, a transcription termination sequence and a signal sequence.

Both expression and cloning vectors generally contain nucleic acid sequence that enable the vector to replicate in one or more selected host cells. Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, polyoma, adenovirus) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors unless these are used in mammalian cells competent for high level DNA replication, such as COS cells.

Most expression vectors are shuttle vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in E. coli and then the same vector is transfected into yeast or mammalian cells even though it is not capable of replicating independently of the host cell chromosome. DNA may also be amplified by insertion into the host genome. However, the recovery of such DNA is more complex than that of exogenously replicated vector because it requires restriction enzyme digestion. DNA can be amplified by PCR and be directly transfected into the host cells without any replication component.

Advantageously, expression and cloning vector contain a selection gene also referred to as selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available from complex media.

As to a selective gene marker appropriate for yeast, any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker gene. Suitable markers for yeast are, for example, those conferring resistance to antibiotics G418,

hygromycin or bleomycin, or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2, LYS2, TRP1, or HIS3 gene.

Since the amplification of the vectors is conveniently done in E. coli, an E. coli genetic marker and an E. coli origin of replication are advantageously included. These can be obtained from E. coli plasmids, such as pBR322, Bluescript vector or a pUC plasmid, e.g. pUC18 or pUC19, which contain both E. coli replication origin and E. coli genetic marker conferring resistance to antibiotics, such as ampicillin.

Suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding a protein of the invention, such as dihydrofolate reductase (DHFR, methotrexate resistance), thymidine kinase, or genes conferring resistance to G418 or hygromycin. The mammalian cell transformants are placed under selection pressure which only those transformants are uniquely adapted to survive which have taken up and are expressing the marker. In the case of the DHFR marker, selection pressure can be imposed by culturing the transformants under conditions in which the methotrexate concentration of selection agent in the medium is successively increased, thereby leading to amplification (at its chromosomal integration site) of both the selection gene and the linked DNA that encodes the multidomain protein of the invention. In that case amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Increased quantities of the protein of the invention are usually synthesized from thus amplified DNA.

Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the nucleic acid of the invention. Such promoter may be inducible or constitutive. The promoters are operably linked to DNA encoding the protein of the invention by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector.

Promoters suitable for use with prokaryotic hosts include, for example, the  $\beta$ -lactamase and lactose promoter systems, alkaline phosphatase, a tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Their nucleotide sequences have been published, thereby enabling the skilled worker operably to ligate them to DNA encoding a protein of the invention, using linkers or adaptors to supply any required restriction sites. Promoters for use

in bacterial systems will also generally contain a Shine-Dalgarno sequence operably linked to the DNA encoding the protein of the invention.

Suitable promoting sequences for use with yeast hosts may be regulated or constitutive and may be derivable from a highly expressed yeast gene, especially a Saccharomyces cerevisiae gene. Such genes are known by those skilled in the art.

DNA transcription from vectors in mammalian hosts may be controlled by promoters derived from the genomes of viruses such as polyoma virus, adenovirus, fowlpox virus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), a retrovirus and Simian Virus 40 (SV40), from heterologous mammalian promoters such as the actin promoter or a very strong promoter, e.g. a ribosomal protein promoter, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding a multidomain protein of the invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are relatively orientation and position independent. Many enhancer sequences are known from mammalian genes (e.g. elastase and globin). However, typically one will employ an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270) and the CMV early promoter enhancer.

Expression vectors used in eukaryotic host cells - suitable envisaged host cells include yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and 3' untranslated regions of eukaryotic or viral DNAs or cDNAs.

An expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector, that upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those with ordinary skill in the art and include those that are replicable in eukaryotic and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

Construction of vectors according to the invention employs conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to

generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression of the DNA of the invention and function are known to those skilled in the art. DNA presence, amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), or in situ hybridization, using an appropriately labelled probe based on a sequence provided herein.

In accordance with another embodiment of the present invention, there are provided cells containing the above-described nucleic acids (i.e., DNA or mRNA). Such host cells such as prokaryote, yeast and higher eukaryote cells may be used for replicating DNA and producing the multidomain protein of the invention. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, such as *E. coli*, e.g. *E. coli* K-12 strains, DH5a, HB101 and XL1 Blue or Bacilli. Further hosts suitable for multidomain protein encoding vectors include eukaryotic microbes such as filamentous fungi or yeast, e.g. *Saccharomyces cerevisiae*. Higher eukaryotic cells include insect and vertebrate cells, particularly mammalian cells. In recent years propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. The host cells referred to in this disclosure comprise cells in in vitro culture as well as cells that are within a host animal.

DNA may be stably incorporated into cells or may be transiently expressed using methods known in the art. Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene, and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, mammalian cells are transfected with a reporter gene to monitor transfection efficiency.

To produce such stably or transiently transfected cells, the cells should be transfected with an amount of protein-encoding nucleic acid sufficient to form the multidomain protein of the invention.

Host cells are transfected or transformed with the above-captioned expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Heterologous DNA may be introduced into host cells by any method known in the

art, such as transfection with a vector encoding a heterologous DNA by the calcium phosphate coprecipitation technique or by electroporation. Numerous methods of transfection are known to the skilled worker in the field. Successful transfection is generally recognized when any indication of the operation of this vector occurs in the host cell. Transformation is achieved using standard techniques appropriate to the particular host cells used.

Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are well known in the art (see, e.g. Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press).

Transfected or transformed cells are cultured using media and culturing methods known in the art, preferably under conditions, whereby multidomain protein encoded by the DNA is expressed. The composition of suitable media is known to those in the art, so that they can be readily prepared. Suitable culturing media are also commercially available.

Within the present invention an effector nucleic acid comprises a desired nucleic acid, which may be e.g. a therapeutically active nucleic acid or a reporter gene, and a specific nucleic acid sequence (also referred to as nucleic acid recognition sequence or cognate structure) recognizable by the nucleic acid binding domain of the multi-domain fusion protein, and, if needed, suitable regulatory elements for the expression of the desired nucleic acid. If required, an effector nucleic acid suitable as a component in the complex of the invention is capable of directing the expression of the desired nucleic acid to be delivered to the target cell. A therapeutically active nucleic acid desired to be delivered to the target cell by the transfer system of the invention may be therapeutically active itself, e.g. by selectively affecting a predetermined process within the target cell, e.g. inhibit synthesis of a particular protein, or it may code for a therapeutically active gene product to be expressed in the target cell. For example, such a gene product may be a new or modified gene, e.g. a tumor suppressor gene or an antibody gene for intracellular immunization, a nucleic acid coding for a prodrug activating enzyme, e.g. herpes simplex thymidine kinase, a nucleic acid coding for an immunomodulator or a foreign antigen, which is suitable for "alienating" the target cell.

The cognate structure may be an RNA or, preferably, a DNA. The effector nucleic acid may comprise one or more, preferably 2 to 8, nucleic acid recognition sequences. If two or more such sequences are present on an effector nucleic acid, advantageously these are arranged in a



way to avoid sterically hindrance of the binding of the multidomain protein of the invention. Preferred is an effector nucleic acid comprising one or more copies, particularly two copies, of the above identified GAL4 recognition sequence. Said sequence binds protein dimers.

Typically, the nucleic acid desired to be expressed in the target cell is a gene, generally in the form of DNA, which encodes a desired protein, e.g. a therapeutically active protein. The gene comprises a structural gene encoding the protein, e.g. an immunomodulatory protein, in a form suitable for processing and secretion as a soluble or cell surface protein by the target cell. For example, the gene encodes appropriate signal sequences which direct processing and secretion of the protein or polypeptide. The signal sequence may be the natural sequence of the protein or an exogenous sequence. The structural gene is linked to appropriate genetic regulatory elements required for expression of the gene-encoded protein or polypeptide by the target cell. These include a promoter and optionally an enhancer element operable in the target cell. The gene can be contained in an expression vector, such as a plasmid or a transposable genetic element, also with the genetic regulatory elements necessary for expression of the gene and secretion of the gene-encoded product. For example, a component of the nucleic acid delivery system of the invention may be a eukaryotic expression plasmid, e.g. a plasmid comprising DNA coding for chloramphenicol acetyltransferase (CAT) driven by an SV-40 promoter, e.g. plasmid pSV2 CAT. The effector nucleic acid may also be a linear DNA fragment.

The effector nucleic acid may comprise bacterial elements suitable for the selection and cloning of the vector.

Suitable eukaryotic expression plasmids or linear DNA fragments carry a promoter structure, the nucleic acid to be introduced and expressed in the target cell, eukaryotic splice and polyadenylation signals, and a specific DNA sequence recognized by the DNA binding domain of the multi-domain fusion protein.

Exemplary genes to be expressed in the target cell also include reporter or marker genes, such as genes encoding luciferase or beta-galactosidase.

If required, the effector nucleic acid may comprise a eukaryotic splice signal or a polyadenylation signal.

The preparation of an effector nucleic acid according to the invention involves methods well known in the art, e.g. those referred to in more detail above.

The type and nature of the nucleic acid to be introduced into the target cell is determined by the effect envisaged to be achieved said target cell, e.g. in case of use in gene therapy by the gene or gene section to be expressed to replace a defective gene, or by the target sequence of a gene the expression of which is to be inhibited. The nucleic acid to be delivered into the cell may be a DNA or a RNA, with no restrictions to the sequence of said nucleic acid.

If the system of the invention is applied to tumor cells to be employed as tumor vaccines, the DNA to be introduced into the cell preferably codes for an immunomodulating protein, e.g. a cytokine or a cell surface antigen suitable for activating a immune response. Combinations of DNAs coding for cytokines, e.g. IL-2 and IFN-g, B7.1, B7.2, MHC1 or MHC2 are considered particularly useful.

If desired, two or more different nucleic acids may be introduced into the cell, e.g. a plasmid comprising cDNAs coding for different proteins, under control of suitable regulatory sequences, or two different plasmids comprising different cDNAs.

The present invention provides means for directing or enhancing the expression of desired proteins (or RNA) in target cells, transgenic animals or insects. The multidomain protein or the protein/nucleic acid complex of the invention is used to introduce nucleic acid into eukaryotic cells, particularly higher eukaryotic cells. Preferred is the use for transfection of mammalian, particularly human cells, e.g. tumor cells, myoblasts, fibroblasts, hepatocytes, endothelial cells or respiratory tract cells. The nucleic acid transfer system of the present invention is useful for the selective DNA transfer into target cells for in vitro applications such as determine the immune response to a particular antigen, and ex vivo or in vivo gene therapy protocols for the therapeutical or prophylactical treatment of mammals in need thereof, particularly humans. Such mammals include those suffering e.g. from inherited or acquired diseases, such as genetic defects, e.g. cystic fibrosis (cystic fibrosis transmembrane conductance gene), hypercholesterolemia (low density lipoprotein (LDL) receptor gene,  $\beta$ -thalassemia, cancerous, autoimmune or infectious diseases. Ex vivo or in vivo application of the protein/nucleic acid complex of the present invention may result in prevention, stabilization or reversion of diseases such as HIV, melanoma, diabetes, Alzheimer disease or heart diseases. According to the invention treatment of cancer may be accomplished by blockade of oncogene expression with antisense constructs, by the introduction and expression of tumor suppressor genes, prodrug activating enzymes or toxic effectors, by administration of tumor vaccines or intracellular immunization. If appropriate, the nucleic acid transfer system of the present invention is applied in combination with a polycation, such as polylysine, polyarginine or

polyornithine, a heterologous polycation comprising two or more different, positively charged amino acid, non-peptidic synthetic polycations, e.g. polyethyleneimine, a protamine, or a histone. Advantageously, the polycation is added after the formation of the protein/nucleic acid complex of the invention, but before the application thereof.

The nucleic acid transfer system of the invention may also be used for immune regulation in organisms, particularly vaccination, or for the production of antibodies for experimental, diagnostic or therapeutic use. For the purpose of vaccination the effector nucleic acid component of the complex of the invention comprises an expressible gene encoding a desired immunogenic protein or peptide, which preferably has a costimulatory effect. The gene is incorporated into the target cell, expressed and following secretion of the gene product as a soluble protein or a cell surface protein an immune response against the immunogenic protein or peptide, such as all or part of the hepatitis B or C antigen, is elicited in the host organism. If the protein against which the immune response is desired is non- or poorly immunogenic, the protein may be coupled to a carrier protein providing for sufficient immunogenicity. This is accomplished by recombinant means by preparing a chimeric DNA construct encoding a fusion protein comprising the protein of the invention and the carrier.

The introduction of genes into target cells with the aim of accomplishing in vivo synthesis of therapeutically effective gene products, e.g. in case of a genetic deficiency to make up for the deficient gene, may also be accomplished using the nucleic acid transfer system of the invention. Apart from "conventional" gene therapy concepts which aim at achieving long-term success of treatment following a one time treatment the present invention provides means for the single or multiple administration of a therapeutically efficient nucleic acid like a pharmaceutical ("gene pharmaceutical"). The nucleic acid transfer system of the present invention may also be useful for transient gene therapy (TGT), preferably for transfer of a recombinant antigen receptor into lymphocytes (especially CTLs). If desired, a constant expression level of transferred genes may be maintained by repeated application of the protein/DNA complex of the invention.

The invention also provides a pharmaceutical composition comprising as effective component a protein/nucleic acid complex of the invention and a pharmaceutically acceptable carrier. Said complex comprises a therapeutically effective nucleic acid, advantageously as a component of a gene construct. In a preferred embodiment the pharmaceutical composition is provided as a lyophilisate or frozen in a suitable buffer. A pharmaceutically acceptable carrier is any carrier in which the protein/nucleic acid complex can be solubilized such that it can be used according

to the invention. A pharmaceutical composition of the invention may additionally comprise an above identified polycation.

Furthermore, the invention provides a transfection kit comprising a carrier, container or vial comprising the protein/nucleic acid complex of the invention and further materials needed for the transfection of higher eukaryotic cells according to the invention. In said kit, the two components of the complex may be stored together or separately, depending on the intended use and the stability of the complex. If stored separately, the two components of the protein/nucleic acid complex of the invention may be mixed immediately before the complex is used.

In vivo therapeutic administration may be via a systemic route, transdermal application, e.g. as an aerosol formulation, and intravenous injection being preferred. Target organs for such applications include liver, spleen, lung, bone marrow and tumors.

Administration for therapeutic purposes may also occur ex vivo involving removal of suitable cells from the patient or another subject, culturing and treatment of the cells with the protein/nucleic acid complex of the invention under conditions allowing internalization of said complex, and subsequent (re-) administration of the treated cells to the patient. Cells suitable for such ex vivo treatment include bone marrow cells, hepatocytes or myeloblasts. Ex vivo treatment is also possible for cancer vaccines. A therapeutic treatment involving cancer vaccines comprises transfection of tumor cells isolated from a patient with a nucleic acid coding for a cytokine and subsequent readministration of the transfected cells producing the cytokine.

In another aspect, the invention relates to a method for the delivery of a nucleic acid into a target cell, particularly a higher eukaryotic cell, said method comprising exposing the cells to the protein/nucleic acid delivery system of the invention in such a way that the complex is internalized and liberated from the endosomes.

The invention particularly relates to the specific embodiments as described in the Examples which serve to illustrate the present invention but should not be construed as a limitation thereof.

**Abbreviations:** *Pseudomonas aeruginosa* exotoxin A = ETA; GAL4 = Galactose gene cluster gene 4; DTT = dithiothreitol; aa = amino acids.

**Example 1****Cloning of the *Pseudomonas aeruginosa* exotoxin A gene fragment encoding amino acids 252 to 366****1.1 Derivation of DNA fragments and purification:**

Plasmid pWW20 (Wels et al., Cancer Res. 52: 6310, 1992) carries a truncated ETA gene encoding amino acids 252 to 613 of exotoxin A from *Pseudomonas aeruginosa* PAK (Gray et al., Proc. Natl. Acad. Sci. USA 81: 2645, 1984; Lory et al., J. Bacteriol. 170: 714, 1989). This gene contains domains II and III, the translocation and ADP-ribosylation domains, respectively, of the wild-type toxin. pWW20 (1 mg) is digested with XbaI and XhoI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 769 bp XbaI/XhoI DNA fragment encoding ETA amino acids 252 to 506 is eluted using the QIAquick gel extraction kit (QIAGEN) according to procedures provided by the manufacturer. The eluted fragment is subsequently digested with MaeII, DNA fragments are separated on a 1.5 % (w/v) agarose gel and the expected 349 bp XbaI/MaeII DNA fragment encoding ETA amino acids 252 to 366 (designated DETA) is eluted as described above.

**1.2 Oligonucleotides:**

A double stranded DNA adaptor with MaeII and EcoRI compatible ends is constructed by annealing 0.5 nmol of the oligonucleotide having the sequence set forth in SEQ ID NO. 7) with 0.5 nmol of the oligonucleotide having the sequence set forth in SEQ ID NO. 8 by incubation at 65°C for 3 min and cooling to room temperature. The sequence of the partially double stranded MaeII/EcoRI adaptor oligonucleotide is

	10	20	30	40	
5'-	CGAGAAGCTT	GAGAGCTCTG	ACTACAAAGA	CGAACTTTAAG.....	- 3'
3'-	..TCTTCGAA	CTCTCGAGAC	TGATGTTTCT	GCTTGAAATT	CTTAA -5.

Bp 1 to 2 represent the MaeII compatible overhanging end, bp 5 to 10 a HindIII restriction site, bp 13 to 18 a SacI restriction site, and bp 42 to 45 the EcoRI compatible overhanging end.

**1.3 Ligation:**

Plasmid pWW191 is a pUC19 derived plasmid wherein the original HindIII restriction site of the multiple cloning site of pUC19 is destroyed and converted into a XbaI restriction site. pWW191 (50 ng) is digested with XbaI and EcoRI, and 30 ng of purified DETA fragment

- 24 -

(see Example 1.1), and 20 pmol MaeII/EcoRI oligonucleotide adaptor are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual/Second Edition, Cold Spring Harbor Laboratory, 1989). The obtained plasmid is designated pWW25. The partial DNA sequence of pWW25 encoding modified exotoxin A from *P. aeruginosa* is shown in SEQ ID NO. 9. Said DNA sequence has the following features:

from 1 to 4 bp	synthetic spacer
from 5 to 349 bp	encoding aa 252 to 366 of <i>P. aeruginosa</i> exotoxin A (DETA)
from 349 to 393 bp	synthetic MaeII/EcoRI adaptor
from 386 to 388 bp	ochre stop codon
from 389 to 394 bp	non-coding synthetic spacer.

## Example 2

### Cloning of the yeast transcription factor GAL4 gene fragment encoding amino acids 2 to 147

Plasmid p02G2A (Yang et al., EMBO J. 10: 2291, 1991) which contains a GAL4 gene fragment encoding amino acids 1 to 147 of GAL4 (Laughon and Gesteland, Mol. Cell. Biol. 4: 260, 1984) is used as a template in a polymerase chain reaction to amplify a GAL4 DNA fragment encoding amino acids 2 to 147 (designated DGAL4).

#### 2.1 Polymerase chain reaction:

12 ng of p02G2A (Yang et al., EMBO J. 10: 2291, 1991) is used for DNA amplification in a 50 µl reaction containing 50 pmol each of the two oligonucleotides complementary to regions in the yeast GAL4 gene 5'- CAGATGAAGCTTCTGTCTTC -3' (SEQ ID NO. 10) and 5'- GAATGAGCTCGATACAGTCAACTG -3' (SEQ ID NO. 11), 4 µl 2.5 mM dNTP (N= G, A, T, C) mixture, 5 µl 10x Taq DNA polymerase buffer (Boehringer Mannheim) and 2.5 U of Taq DNA polymerase (Boehringer Mannheim). Taq DNA polymerase is added after initial denaturation at 94°C for 2 min. For 30 cycles annealing is performed for 1 min at 55°C, primer extension for 1 min at 72°C, denaturation for 1 min at 94°C. Finally, amplification is completed by a 3 min primer extension step at 72°C.

## 2.2 Derivation of the GAL4 DNA fragment and purification:

Amplification products are separated on a 1.2 % (w/v) agarose gel (ultra pure agarose, BRL), DNA of the expected size is eluted, and subsequently digested with HindIII and SacI. The expected 441 bp DGAL4 DNA fragment encoding amino acids 2 to 147 of GAL4 is separated on a 1.2 % agarose gel and purified by elution from the gel as described above.

## 2.3 Ligation:

pWW25 (50 ng) digested with HindIII and SacI, and 30 ng of purified amplification product are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E.coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual/Second Edition, Cold Spring Harbor Laboratory, 1989). The obtained plasmid is designated pWW35. The partial DNA sequence of pWW35 encoding partial GAL4 from yeast is shown in SEQ ID NO: 12. The features of said sequence are as follows:

from 1 to 438 bp      encoding amino acids 2 to 147 of yeast GAL4  
from 439 to 443 bp    synthetic spacer.

## Example 3

### Isolation of RNA from the hybridoma cell line FRP5

#### 3.1 Growth of FRP5 cells:

FRP5 hybridoma cells ( $1 \times 10^8$ ; deposited under the Budapest Treaty on November 21, 1990 at the European Collection of Animal Cell Cultures (ECACC) in Porton Down, Salisbury, UK, under accession number 90112115) are grown in suspension culture at 37°C in DMEM (Seromed) further containing 10% FCS (Amimed), 1 mM sodium pyruvate (Seromed), 2 mM glutamine (Seromed), 50 mM 2-mercaptoethanol and 100 mg/ml of gentamycin (Seromed) in a humidified atmosphere of air and 7.5% CO<sub>2</sub> in 175 cm tissue culture flasks (Falcon 3028). The cells are harvested by centrifugation, washed once in PBS, flash frozen in liquid nitrogen and kept frozen as a pellet at - 80°C in a clean, sterile plastic capped tube.

#### 3.2 Extraction of total cellular RNA from FRP5 cells:

Total RNA is extracted using the acid guanidinium thiocyanate-phenol-chloroform method described by Chomczynski & Sacchi (Anal. Biochem. 162: 156, 1987). Cell pellets of FRP5

cells ( $1 \times 10^8$ ) are thawed directly in the tube in the presence of 10 ml of denaturing solution (4 M guanidinium thiocyanate (Fluka), 25 mM sodium citrate, pH 7.0, 0.5% N-lauroyl-sarcosine (Sigma), 0.1M 2-mercaptoethanol). The solution is homogenized at room temperature. Sequentially, 1 ml of 2 M sodium acetate, pH 4, 10 ml of phenol (water saturated) and 2 ml of chloroform-isoamyl alcohol mixture (49:1) are added to the homogenate. The final suspension is shaken vigorously for 10 sec and cooled on ice for 15 min. The samples are centrifuged at  $10,000 \times g$  for 20 min at  $4^\circ\text{C}$ . After centrifugation, RNA which is present in the aqueous phase is mixed with 10 ml of isopropanol and placed at  $-20^\circ\text{C}$  for 1 h. The RNA precipitate is collected by centrifugation, the pellet dissolved in 3 ml water and the RNA reprecipitated by addition of 1 volume of isopropanol at  $-20^\circ\text{C}$ . After centrifugation and washing the pellet in ethanol, the final pellet of RNA is dissolved in water. The method yields approximately 300 mg of total cellular RNA. The final purified material is stored frozen at  $-20^\circ\text{C}$ .

### **3.3 Isolation of poly(A) containing RNA:**

Poly(A) containing RNA is selected from total RNA by chromatography on oligo(dT)-cellulose (Boehringer Mannheim) as described originally by Edmonds et al. (Proc. Natl. Acad. Sci. USA 68: 1336, 1971) and modified by Maniatis et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, p. 197). The poly(A)-containing RNA is prepared as described in the published procedure with the exception that the RNA is eluted from the oligo(dT)-cellulose with water rather than SDS-containing buffer. The poly(A)-containing RNA is precipitated with ethanol and collected by centrifugation. The yield of poly(A)-containing RNA is approximately 30 mg from 300 mg of total cellular RNA. The final purified material is stored frozen at  $-20^\circ\text{C}$ .

### **Example 4**

#### **Cloning of functional heavy and light chain rearrangements from the FRP5 hybridoma cell line**

Poly(A)-containing RNA isolated from FRP5 hybridoma cells as described in Example 3.3 provides the source for cDNA synthesis and subsequent amplification of V-region minigenes. Amplification products of the expected size are purified from agarose gels and cloned into appropriate vectors. Functional rearrangements are identified by sequencing.



**4.1 Oligonucleotides:**

Oligonucleotide MCK2 is designed to be complementary to a region in the murine immunoglobulin k (kappa) constant minigene and has the nucleotide sequence set forth in SEQ ID NO. 13. Oligonucleotide MCHC2 is designed to be complementary to a region in the murine immunoglobulin g1 constant minigene and has the nucleotide sequence set forth in SEQ ID NO. 14. The oligonucleotides VH1FOR, VH1BACK, and VK1BACK are designed by Orlandi et al. (Proc. Natl. Acad. Sci. USA 86: 3833, 1989) to match consensus sequences.

VH1FOR: 5' - TGAGGAGACGGTGACCGTGGTCCCTTGGCCCCAG - 3'  
 VH1BACK: 5' - AGGT (C/G) (C/A) A (G/A) CTGCAG (G/C) AGTC (T/A) GG - 3'  
 VK1BACK: 5' - GACATTCAGCTGACCCAGTCTCCA - 3'

**4.2 cDNA synthesis:**

55 ng of poly(A)-containing RNA is dissolved in a buffer containing 50 mM Tris-HCl, pH 8.3, 3 mM magnesium chloride, 10 mM DTT, 75 mM KCl, 400 mM dNTPs (N = G, A, T and C), 100 mg BSA (molecular biology grade, Boehringer Mannheim), 100 U RNase inhibitor (Boehringer Mannheim), 25 pmol MCK2 and 25 pmol MCHC2. The RNA is denatured at 70°C for 5 min and then chilled on ice for 2 min. After addition of 200 U of MMLV reverse transcriptase (Gibco, BRL) cDNA synthesis is achieved by incubation for 1 h at 37°C.

**4.3 Polymerase chain reaction:**

One tenth of the cDNA reaction is used for DNA amplification in buffer containing 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, 10 mM b-mercaptoethanol, 200 mM dNTPs (N= G, A, T and C), 0.05% Tween-20% (Merck), 0.05% NP-40% (Merck), 10% DMSO (Merck), 25 pmol oligonucleotide 1 (see below), 25 pmol oligonucleotide 2 (see below) and 2.5 U Amplitaq<sup>®</sup> DNA polymerase (Perkin Elmer Cetus). Taq polymerase is added after initial denaturation at 93°C for 1 min and subsequent annealing at 37°C. In the first 4 cycles primer extension is performed at 71°C for 0.2 min, denaturation at 93°C for 0.01 min and annealing at 37°C for 0.2 min. For the last 25 cycles the annealing temperature is raised to 62°C. Finally, amplification is completed by a 3 min primer extension step at 71°C.

PCR Product	oligonucleotide 1	oligonucleotide 2
H	VH1FOR	VH1BACK
LC	MCK2	VK1BACK

#### 4.4 Modification and purification:

Amplified material is extracted with  $\text{CHCl}_3$  and precipitated with ethanol in the presence of 200 mM LiCl. To facilitate cloning, blunt ends are created by a 3 min treatment with 1 U T4 DNA polymerase (Boehringer Mannheim) in 66 mM Tris-acetate, pH 7.9, 132 mM potassium acetate, 20 mM magnesium acetate, 1 mM DTT, 200 mg/ml BSA (molecular biology grade, Boehringer Mannheim), and 400 mM dNTPs (N = G, A, T and C). The polymerase is inactivated by heating for 15 min at 65°C before phosphorylation of the DNA with 10 U T4 polynucleotide kinase (Pharmacia) at 37°C for 1 h. For this purpose the buffer is adjusted to 50 mM EDTA and 1 mM ATP. The modified amplification products are separated on a 1.2% (w/v) agarose gel (ultra pure DNA grade agarose, Biorad) and DNA of the expected size is eluted by means of DEAE NA 45 membranes (Schleicher & Schuell).

#### 4.5 Ligation:

Bluescript<sup>®</sup> KS+ (70 ng) linearized with XbaI, treated with Klenow DNA polymerase (Boehringer Mannheim) to give blunt ends and dephosphorylated with calf intestinal phosphatase, and 30 ng of purified amplification product are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of the ligation mixture is used to transform *E. coli* K803 to obtain ampicillin resistant colonies. These are screened for the desired ligation products using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982). The following plasmids are obtained:

PCR product	Plasmid clones
H	pMZ16/1
LC	pMZ18/1

#### 4.6 Sequencing:

Sequencing is done using Sequenase<sup>®</sup> kits (United States Biochemicals) with T3 and T7 oligonucleotide primers according to procedures provided by the manufacturer. Plasmid pMZ18/1 contains a functional FRP5 kappa light chain variable domain insert. Plasmid pMZ16/1 contains a functional FRP5 heavy chain variable domain insert. Plasmids pMZ16/1 and pMZ18/1 are used as a source for further subcloning steps.

**Example 5****Construction of the MAb FRP5 single-chain Fv gene****5.1 Construction and sequence of a cloning linker for the heavy and light chain variable domain cDNAs:**

Using oligonucleotides, a linker sequence which allows the cloning of PCR amplified mouse heavy chain variable domain cDNA as a PstI/BstEII fragment and of PCR amplified mouse kappa light chain variable domain cDNA as a PvuII/BglII fragment is constructed as described by Wels et al., *Biotechnology* 10: 1128, 1992. This creates an open reading frame in which heavy and light chain variable domains are connected by a sequence coding for the 15 amino acid stretch Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO:49). This amino acid linker has been shown to allow correct folding of an antigen binding domain present in heavy and light chain variable domains in a single-chain Fv (Huston et al., *Proc. Natl. Acad. Sci. USA* 85: 5879, 1988).

For the construction of the cloning linker the 6 complementary oligonucleotides 1A (SEQ ID NO. 15), 1B (SEQ ID NO. 16), 2A (SEQ ID NO. 17), 2B (SEQ ID NO. 18), 3A (SEQ ID NO. 19), 3B (SEQ ID NO. 20) are used.

40 pM of oligonucleotides 1B, 2A, 2B, 3A are phosphorylated at the 5' end using T4 polynucleotide kinase (Boehringer Mannheim) in four separate reactions in a total volume of 20 ml following the method described by Maniatis et al., *supra*. Oligonucleotides 1A and 3B are not phosphorylated in order to avoid self ligation of the linker in the final ligation reaction. After the kinase reaction, the enzyme is inactivated by incubation at 70°C for 30min. In three separate reactions, each containing 40 pM of two oligonucleotides in a total volume of 40 ml, non-phosphorylated 1A and phosphorylated 1B, phosphorylated 2A and phosphorylated 2B, and phosphorylated 3A and non-phosphorylated 3B are mixed. Hybridization of the oligonucleotides in the three reactions is carried out by heating to 95°C for 5 min, incubation at 65°C for 5 min and slowly cooling to room temperature. 10ml from each of the three reactions are mixed, 4 ml of 10 x ligation buffer (Boehringer) and 4 units of T4 DNA ligase (Boehringer) are added and the total volume is adjusted to 40 ml with sterile water. The annealed pairs of oligonucleotides are ligated into one linker sequence for 16 h at 14°C. The reaction mixture is extracted with an equal volume of phenol/chloroform (1:1) followed by re-extraction of the aqueous phase with an equal volume of chloroform/isoamylalcohol (24:1). The aqueous phase is collected, 0.1 volumes of 3 M sodium acetate pH 4.8 and 2 volumes of ethanol are added, and the DNA is precipitated at -70°C for 4 h and collected by

centrifugation. The resulting linker sequence has a SphI and a XbaI adaptor end. It is ligated to SphI and XbaI digested pUC19 in a reaction containing 100 ng of ligated linker and 200 ng of SphI/XbaI digested pUC19. After transformation into *E. coli* XL1 Blue% (Stratagene), plasmid DNA from 4 independent colonies is isolated by the alkaline lysis mini-preparations method (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982). The DNA sequence of the linker cloned in pUC19 is determined by sequencing double stranded DNA in both directions with Sequenase II (United States Biochemicals) and pUC universal and reverse primers (Boehringer) following the manufacturer's protocol. Three out of the four recombinant pUC19 isolates sequenced contain the correct linker sequence. One of them is designated pWW19 and used in the further experiments. The partial DNA sequence of pWW19 which is set forth in SEQ ID NO. 21 has the following features:

from 30 to 35 bp	PstI site
from 38 to 44 bp	BstEII site for subcloning of heavy chain variable domain
from 54 to 98 bp	coding sequence of (GlyGlyGlyGlySer) <sub>3</sub> linker
from 105 to 110 bp	PvuII site
from 112 to 117 bp	BglII site
from 120 to 125 bp	BclI site for subcloning of light chain variable domain

## 5.2 Preparation of a plasmid for the subcloning of variable domains:

The Fv cloning linker sequence is derived as a 144 bp HindIII/SacI fragment from pWW19 and inserted into HindIII/SacI digested Bluescript% KS+ (ex PvuII) (Stratagene) which contains no PvuII restriction sites. The resulting plasmid, pWW15, allows cloning of heavy and light chain variable domains as PstI/BstEII and PvuII/BglII fragments, respectively.

### 5.2.1 Subcloning of the FRP5 heavy chain variable domain:

Plasmid pMZ16/1 is digested with PstI and BstEII and the 338 bp heavy chain variable domain fragment of FRP5 is isolated. It is cloned into PstI/BstEII digested pWW19 yielding the plasmid pWW31.

### 5.2.2 Mutation of the FRP5 light chain variable domain and assembly of the Fv fusion gene:

To facilitate subcloning of the FRP5 light chain variable domain into the Fv cloning linker, a PvuII restriction site and a BglII restriction site are introduced at the 5' and 3' ends, respectively, of the coding region. The FRP5 light chain variable domain coding region is isolated as a SacI/BamHI fragment from pMZ18/1. SacI and BamHI are restriction sites of the Bluescript<sup>®</sup> polylinker present in pMZ18/1. The fragment contains the complete light chain variable domain fragment of 392 bp amplified by PCR using the oligonucleotide MCK2 (see above). This fragment is mutated and amplified by PCR using the oligonucleotides

V<sub>L</sub>5': 5'-GACATTCAGCTGACCCAG-3' (SEQ ID NO. 22) and  
 V<sub>L</sub>3': 5'-GCCCGTTAGATCTCCAATTTTGTCCCCGAG-3' (SEQ ID NO. 23)

for the introduction of a PvuII restriction site at the 5' end (V<sub>L</sub>5') and a BglII restriction site at the 3' end (V<sub>L</sub>3') of the kappa light chain variable domain DNA. 20 ng of the FRP5 variable light chain SacI/BamHI fragment are used as a template in a 100 µl reaction following the PCR conditions described in Example 4.3. The amplified and mutated fragment is isolated after PvuII/BglII digestion as a 309 bp fragment from a 1.5% agarose gel and cloned into PvuII/BglII digested pWW15 generating plasmid pWW41. The FRP5 kappa light chain variable domain is isolated as a BstEII/XbaI fragment from pWW41 and inserted into BstEII/XbaI digested pWW31. Thus the FRP5 heavy chain variable domain in pWW31 and the FRP5 kappa light chain variable domain are fused to one open reading frame. Double stranded DNA of three independent clones is sequenced with Sequenase II<sup>®</sup> kit (United Biochemicals) in both orientations using pUC universal and reverse primers (Boehringer) following the manufacturer's protocol. One of the plasmids carrying the FRP5 heavy chain variable domain fused to the mutated FRP5 light chain variable domain is selected and designated pWW52.

### 5.3 Mutation of the single-chain Fv(FRP5) gene:

To allow gene fusion with the single-chain Fv(FRP5) encoding gene from pWW52 a stop codon at sequence the 3' end position in pWW52 is deleted as follows: plasmid DNA of pWW52 is digested with BstEII and BglII and the linker sequence and FRP5 light chain variable domain encoding fragment is isolated. In another digestion, pWW52 is cleaved with BstEII and BclI. Thus, the large fragment containing vector sequences and the FRP5 heavy chain variable domain encoding sequence is isolated. The BstEII/BglII V<sub>L</sub> fragment is now inserted into BstEII/BclI cleaved pWW52 containing V<sub>H</sub>. In the resulting plasmid, pWW53,

the BglII/BclI junction is determined by sequencing double stranded DNA as described above (SEQ ID NO. 24).

### **Example 6**

#### **Construction of plasmid pWW152-5**

##### **6.1 Oligonucleotides:**

A double stranded DNA adaptor with HindIII and PstI compatible ends is constructed by annealing 0.5 nmol of the oligonucleotide having the sequence set forth in SEQ ID NO. 25 with 0.5 nmol of the oligonucleotide having the sequence set forth in SEQ ID NO. 26 by incubation at 65°C for 3 min and cooling to room temperature. The structure of the oligonucleotide adaptor is:

5'- .AGCTTCAGGTACAACTGCA. - 3'

3'- .....AGTCCATGTTG..... - 5'.

##### **6.2 Derivation of pWW15 vector fragment and purification:**

Plasmid pWW 15 (1 mg; see Example 5.2) is digested with HindIII and PstI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 3.1 kb HindIII/PstI vector fragment is eluted.

##### **6.3 Ligation of pWW15 HindIII/PstI fragment and oligonucleotide adaptor:**

pWW15 (50 ng) HindIII/PstI fragment and 50 pmol oligonucleotide adaptor are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method. The obtained plasmid is designated pWW152.

##### **6.4 Derivation of DNA fragments and purification:**

Plasmid pWW152 (1 mg) is digested with PstI and XbaI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultr pure agarose, BRL) and the expected 3.1 kb PstI/XbaI vector fragment is eluted. Plasmid pWW53 (1 mg) is digested with PstI and XbaI. DNA fragments are separated and the PstI/XbaI DNA fragment encoding scFv(FRP5) is eluted as described above.

**6.5 Ligation of pWW152 vector fragment and the scFv(FRP5) gene fragment:**

Plasmid pWW 152 (50 ng) digested with PstI and XbaI, and 30 ng of purified PstI/XbaI scFv(FRP5) fragment are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of the ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method. The obtained plasmid is designated pWW 152-5. The DNA sequence of the scFv(FRP5) gene between the HindIII and XbaI restriction site is identical to the sequence of plasmid pWF46-5 (see Example 8.) from nucleotide position bp 109 to bp 845 shown in SEQ ID NO: 1.

**Example 7****Construction of the single-chain Fv (FRP5)-DETA-DGAL4 fusion gene****7.1 Derivation of DNA fragments and purification:**

pWW35 (1 mg) is digested with XbaI and EcoRI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 821 bp XbaI/EcoRI DNA fragment carrying the DETA-DGAL4 fusion gene and adjacent synthetic sequences is eluted. Plasmid pWW152-5 (1 mg) carrying the gene encoding the erbB-2 specific single-chain Fv (scFv) molecule scFv(FRP5) is digested with HindIII and XbaI. DNA fragments are separated and the expected 735 bp HindIII/XbaI DNA fragment carrying the scFv gene is eluted as described above.

**7.2 Ligation:**

pFLAG-1 (50 ng) (IBI Biochemicals) digested with HindIII and EcoRI, and 30 ng of purified HindIII/XbaI scFv(FRP5) fragment, and 30 ng of purified XbaI/EcoRI D E T A - D G A L 4 fragment are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method. The obtained plasmid is designated pWF45-5.

**Example 8****Construction of an expression plasmid carrying the scFv(FRP5)-DETA-DGAL4 fusion gene****8.1 Derivation of DNA fragments and purification:**

pWF45-5 (1 mg) is digested with HindIII and SalI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 907 bp HindIII/SalI DNA fragment carrying the scFv(FRP5)-DETA<sub>252-308</sub> (coding for ETA amino acids 252 to 308) fusion gene is eluted. pWF45-5 (1 mg) is digested with SalI and XbaI. DNA fragments are separated and the expected 655 bp SalI/XbaI DNA fragment encoding DETA<sub>309-366</sub>-DGAL4 is eluted as described above.

**8.2 Ligation:**

Plasmid pFLAG-1 is digested with HindIII and XbaI and a double-stranded DNA linker encoding 6 His residues at its 5' end and the original HindIII-, EcoRI- and XbaI-restriction sites of pFLAG-1 at its 3' end are inserted 3' of the FLAG epitope. The resulting plasmid pSW50 (50 ng) digested with HindIII and XbaI, and 30 ng of purified HindIII/SalI scFv(FRP5)-DETA<sub>252-308</sub> fragment, and 30 ng of purified Sal/XbaI DETA<sub>309-366</sub>-DGAL4 fragment are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., supra). The obtained plasmid is designated pWF46-5. The partial DNA sequence of pWF46-5 is shown in SEQID NO. 1. Said sequence has the following features:

from 1 to 63 bp	encoding the <i>E. coli</i> ompA signal peptide
from 64 to 87 bp	encoding the synthetic FLAG epitope
from 88 to 114 bp	synthetic spacer sequence
from 115 to 834 bp	encoding scFv(FRP5)
from 835 to 843 bp	synthetic spacer sequence
from 844 to 1188 bp	encoding amino acids 252 to 366 of ETA
from 1189 to 1191bp	synthetic spacer sequence
from 1192 to 1629 bp	encoding amino acids 2 to 147 of yeast GAL4
from 1630 to 1653 bp	synthetic spacer including sequence coding for KDEL retention signal



from 1654 to 1656 bp    ochre stop codon  
from 1657 to 1692 bp    non-coding synthetic spacer

The deduced amino acid sequence of the pWF46-5 encoded scFv(FRP5)-DETA-DGAL4 protein including a peptide spacer at the N-terminus (aa 1 to 17) is shown in SEQ ID NO. 2.

#### **Example 9**

##### **Bacterial expression and purification of scFv(FRP5)-DETA-D GAL4:**

Plasmid pWF46-5 is transformed into *E.coli* K12. A recombinant single colony is grown overnight in 50 ml LB medium containing 100 µg/ml ampicillin and 0.6 % glucose. The overnight culture is diluted 1:30 in 1 l fresh LB medium containing 100 µg/ml ampicillin and 0.6 % glucose and grown at 37°C to an OD<sub>550</sub> of 0.5. Isopropyl-beta-D-thiogalactopyranoside (IPTG) is added to a final concentration of 0.5 mM and expression is induced for 1.5 h at room temperature. The cells are harvested at 4°C by centrifugation at 17,000 g for 10 min in a J2-HS centrifuge (Beckman) using a JA10 rotor (Beckman).

##### **9.1 Isolation of scFv(FRP5)-ΔETA-ΔGAL4 from the bacterial cell pellet:**

The bacterial cell pellet is resuspended in 30 ml of lysis buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 µM ZnCl<sub>2</sub>, 0.3 mM PMSF, 8 M urea. The bacterial cells are lysed by sonication for 3 min on ice. The lysate is gently shaken for 1.5 h at room temperature and then centrifuged at 4 °C in a TL100 ultracentrifuge (Beckman) for 25 min at 100,000 g. The supernatant is collected, 10 mM imidazole final concentration is added and stored at 4°C.

##### **9.2 Purification of scFv(FRP5)-ΔETA-ΔGAL4 by affinity chromatography:**

A nickel-NTA affinity column (QIAGEN) is equilibrated in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 µM ZnCl<sub>2</sub>, 0.3 mM PMSF, 8 M urea, 10 mM imidazole. Cleared supernatant from step 9.1 containing the scFv(FRP5)-ΔETA-ΔGAL4 protein is passed through the column. The column is washed with equilibration buffer. Bound protein is eluted with 250 mM imidazole in equilibration buffer. The eluate is first dialysed for 16 h at 4°C against 60 volumes of 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 5 mM MgCl<sub>2</sub>, 10 µM ZnCl<sub>2</sub>, 20% glycerol, 400 mM L-arginine. L-arginine is removed by a second dialysis for 16 h at 4°C against 60 volumes of the same dialysis buffer lacking the L-arginine. The dialysed protein solution is clarified at 4°C by centrifugation at 23,000 g for 30 min in a J2-HS centrifuge (Beckman) using a JA20 rotor (Beckman). The supernatant is collected and stored at 4°C. Protein purity is determined by

SDS-polyacrylamide gel electrophoresis in a 12.5 % polyacrylamide gel. Typical protein purity after purification is greater than 90 %.

### Example 10

#### Construction of eukaryotic expression plasmids containing GAL4 recognition sequences

A family of plasmids each containing two GAL4 recognition sequences are constructed. The plasmids consist of a bacterial origin of replication, a bacterial selectable marker gene, and a eukaryotic expression unit with the following general structure:

eukaryotic promoter - gene of interest - intron - dimeric GAL4 recognition sequence - polyadenylation site

#### 10.1 Oligonucleotides:

A double stranded DNA adaptor with HindIII and BamHI compatible ends is constructed by annealing 0.5 nmol of the oligonucleotide set forth in SEQ ID NO. 27 with 0.5 nmol of the oligonucleotide set forth in SEQ ID NO. 28 by incubation at 65°C for 3 min and cooling to room temperature. The partially double stranded DNA oligonucleotide containing two GAL4 binding motifs is designated G4. The structure of the oligonucleotide adaptor is shown below:

10	20	30	40	50
AGCTTGGATC CGGAGGACAG TCCTCCGGAG ACCGGAGGAC AGTCCTCC... ..				
....ACCTAG GCCTCCTGTC AGGAGGCCTC TGGCCTCCTG TCAGGAGGCT AG.				

The features are as follows:

bp 1 to 4 HindIII compatible overhanging end; bp 6 to 11 BamHI restriction site; bp 11 to 27 GAL4 binding motif I; bp 28 to 32 spacer sequence; bp 33 to 49 GAL4 binding motif II; bp 48 to 52 BamHI compatible overhanging end. Ligation of the BamHI compatible end to the BamHI site of a restriction fragment results in the destruction of that BamHI restriction site.

#### 10.2 Derivation of pSV2CAT DNA fragments and purification:

Plasmid pSV2CAT (1 mg) (Gorman et al., Mol. Cell. Biol. 2: 1044, 1982) is digested with HindIII and BamHI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 3.4 kb HindIII/BamHI pSV2D vector fragment and the 1.6

kb HindIII/BamHI insert fragment carrying the chloramphenicol acetyl transferase (CAT) gene and adjacent vector sequences are eluted.

#### **10.3 Ligation of pSV2D fragment and oligonucleotide adaptor:**

pSV2D (50 ng) HindIII/BamHI fragment and 50 pmol oligonucleotide adaptor are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E.coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., supra). The following plasmid is obtained: pSV2D-G4.

#### **10.4 Ligation of pSV2D-G4 and CAT DNA fragment:**

pSV2D-G4 (50 ng) digested with HindIII and BamHI and 30 ng of the 1.6 kb HindIII/BamHI insert fragment from pSV2CAT carrying the chloramphenicol acetyl transferase (CAT) gene and adjacent vector sequences are ligated, the ligation mixture is transformed into *E.coli*, and ligation products are screened as described in 10.3. The following plasmid is obtained: pSV2CAT-G4.

#### **10.5 Derivation of the pSV2NEO DNA fragment and purification:**

pSV2NEO (1 mg) (Southern & Berg, J. Mol. Appl. Genet. 1: 327, 1982) is digested with HindIII and BamHI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 2.3 kb HindIII/BamHI insert fragment carrying the neomycin phosphoribosyl transferase (NEO) gene and adjacent vector sequences is eluted.

#### **10.6 Ligation of pSV2D-G4 and NEO DNA fragment:**

Plasmid pSV2D-G4 (50 ng) digested with HindIII and BamHI and 30 ng of the 2.3 kb HindIII/BamHI insert fragment carrying the neomycin phosphoribosyl transferase (NEO) gene and adjacent vector sequences are ligated, the ligation mixture is transformed into *E.coli*, and ligation products are screened as described in 10.3. The following plasmid is obtained: pSV2NEO-G4.

#### **10.7 Derivation of the pCH110 b-galactosidase DNA fragment and purification:**

Plasmid pCH110 (1 mg) (Pharmacia) is digested with HindIII and BamHI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 3.7 kb HindIII/BamHI insert fragment carrying the b-galactosidase gene and adjacent vector sequences is eluted.

**10.8. Ligation of pSV2D-G4 and b-galactosidase DNA fragment:**

pSV2D-G4 (50 ng) digested with HindIII and BamHI and 30 ng of the 3.7 kb HindIII/BamHI insert fragment carrying the b-galactosidase gene and adjacent vector sequences are ligated, the ligation mixture is transformed into E.coli, and ligation products are screened as described in 6.3. The following plasmid is obtained: pSV2bGal-G4.

**10.9 Ligation of pSV2D fragment and b-galactosidase DNA fragment:**

pSV2D (50 ng) HindIII/BamHI fragment and 30 ng of the 3.7 kb HindIII/BamHI insert fragment carrying the b-galactosidase gene and adjacent vector sequences are ligated, the ligation mixture is transformed into E.coli, and ligation products are screened as described in 10.3. The following plasmid is obtained: pSV2bGal.

**10.10 Derivation of the pSVD5LUC luciferase DNA fragment and purification:**

pSVD5LUC (1 mg) (Gouilleux et al., Nuc. Acid Res. 19: 1563, 1991) is digested with HindIII and BamHI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 2.7 kb HindIII/BamHI insert fragment carrying the luciferase gene and adjacent vector sequences is eluted.

**10.11 Ligation of pSV2D-G4 and luciferase DNA fragment:**

pSV2D-G4 (50 ng) digested with HindIII and BamHI and 30 ng of the 2.7 kb HindIII/BamHI insert fragment carrying the luciferase gene and adjacent vector sequences are ligated, the ligation mixture is transformed into E.coli, and ligation products are screened as described in 10.3. The following plasmid is obtained: pSV2LUC-G4.

**10.12 Ligation of pSV2D fragment and luciferase DNA fragment:**

pSV2D (50 ng) HindIII/BamHI fragment and 30 ng of the 2.7 kb HindIII/BamHI insert fragment carrying the luciferase gene and adjacent vector sequences are ligated, the ligation mixture is transformed into E.coli, and ligation products are screened as described in 6.3. The following plasmid is obtained: pSV2LUC.

**Example 11****Determination of DNA binding activity of scFv(FRP5)-DETA-DGAL4 protein**

The DNA binding activity and specificity of the scFv(FRP5)-ETA-DGAL4 protein described in Example 9 is analyzed in gel retardation assays.

### 11.1 5'-DNA labeling reaction:

5 pmol of G4 partially double stranded DNA oligonucleotide described in Example 6.1 containing 2 GAL4 binding motifs is incubated for 45 min at 37°C with 50 mCi (g-<sup>32</sup>P) dATP (10 mCi/ml) (Amersham) and 10 U T4 polynucleotide kinase (Boehringer Mannheim) in a buffer containing 50 mM Tris-HCl, pH 7.6, 10 mM magnesium chloride, 5 mM DTT, and 0.1 mM EDTA. <sup>32</sup>P-labeled G4 oligonucleotide is purified by extraction with 1 volume of a 1:1 mixture of Tris-HCl, pH 8.0 saturated phenol and chloroform/isoamyl alcohol (24:1) followed by extraction of the aqueous phase with 1 volume of chloroform/isoamyl alcohol (24:1) and precipitation of G4 oligonucleotide from the aqueous phase by the addition of 1 volume of 4 M ammonium acetate, 0.2 volumes of 1 M magnesium chloride and 2 volumes of ethanol at -20°C overnight. The oligonucleotide pellet is dried under vacuum and the dry pellet is dissolved in water to a final concentration of 100 nM (1124 cpm/fmol).

### 11.2 Gel retardation assay:

1 pmol scFv(FRP5)-DETA-DGAL4 protein and 50 fmol <sup>32</sup>P-labeled G4 oligonucleotide are mixed in a 20 ml reaction in a buffer containing 50 mM Hepes, pH 7.5, 50 mM potassium chloride, 5 mM magnesium chloride, 10 mM zinc chloride, 6 % glycerol, 200 mg/ml bovine serum albumin and 50 mg/ml poly-(dI-dC) (Boehringer Mannheim) and incubated for 30 min at room temperature. The samples are separated on a non-denaturing poly-acrylamide gel as described by Carey et al. (J. Mol. Biol. 209: 423, 1989). A 18 x 20 cm 4.5 % acrylamide gel is prepared in a buffer at pH 8.4 containing 45 mM Tris-base, 45 mM boric acid, 1 % glycerol. Samples are separated by electrophoresis for 2 to 3 h at 200 V with a running buffer at pH 8.4 containing 45 mM Tris-base, 45 mM boric acid, 1 % glycerol. Bands are visualized by overnight exposure of the gel at -80°C with X-OMAT DS film (Kodak). The intensity of bands is quantified using a FUJIX BAS1000 phosphorimager (Fuji). As a result of the gel retardation assay two bands with decreased mobility compared to the free probe are visible, the more intense higher molecular weight complex representing two scFv(FRP5)-DETA-DGAL4 dimers bound to the tandem GAL4 binding sites on the radioactive probe, the lower molecular weight complex representing one scFv(FRP5)-DETA-DGAL4 dimer bound to one of the tandem GAL4 binding sites on the radioactive probe. The unbound free probe is visible at the bottom of the gel.

### 11.3 Competition assay:

A gel retardation assay is performed exactly as described in Example 10.2 by incubating 1 pmol scFv(FRP5)-DETA-DGAL4 protein and 50 fmol <sup>32</sup>P-labeled G4 oligonucleotide in the presence of increasing amounts from 50 fmol to 12.8 pmol of non-radioactive G4

oligonucleotide as a competitor resulting in G4/<sup>32</sup>P-G4 ratios of 1, 4, 16, 64, 256. The results of the competition assay show that the binding of scFv(FRP5)-DETA-DGAL4 to the <sup>32</sup>P-labeled G4 oligonucleotide is specific since increasing concentrations of the non-radioactive competitor reduce the amount of complex consisting of scFv(FRP5)-DETA-DGAL4 and <sup>32</sup>P-labeled G4 oligonucleotide exponentially.

### **Example 12**

#### **Determination of p185 erbB-2 binding specificity of**

##### **scFv(FRP5)-DETA-DGAL4 protein**

The p185 erbB-2 binding activity and specificity of the scFv(FRP5)-DETA-DGAL4 protein described in Example 9. is analyzed in an enzyme-linked immunosorbent assay (ELISA).

##### **12.1 Preparation of ELISA plates:**

SK-BR-3 human breast carcinoma cells (ATCC HTB30) are seeded in 96-well tissue culture plates at a density of  $1 \times 10^5$  cells per well and grown for 24 h at 37°C. The cells are washed twice with PBS, fixed with 3.7 % formaldehyde in PBS for 20 min at room temperature and blocked with a buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM sodium chloride (TBS) and 3 % bovine serum albumin.

##### **12.2 Binding assay:**

100 ml of scFv(FRP5)-DETA-DGAL4 protein in TBS containing 3 % bovine serum albumin at concentrations ranging from 60 pM to 1 mM are added to the cells in triplicates and incubated for 1 h at 37°C in a humidified atmosphere. The cells are washed twice with TBS and 100 ml of a 1:2000 dilution of a polyclonal rabbit antiserum raised against purified Pseudomonas exotoxin A (Wels et al., Cancer Res. 52: 6310, 1992) in TBS containing 3 % bovine serum albumin are added to each well for 30 min at 37°C in a humidified atmosphere. The cells are washed twice with TBS and 100 ml of a 1:4000 dilution of alkaline phosphatase-coupled goat anti-rabbit serum (Sigma) in TBS containing 3 % bovine serum albumin are added to each well for 30 min at 37°C in a humidified atmosphere. The cells are washed twice with TBS and the activity of bound alkaline phosphatase is detected by incubation of the cells with 100 ml/well of 1 mg/ml p-nitrophenyl-phosphate in 1 M Tris-HCl, pH 8.0. Alkaline phosphatase activity in each well is quantitated by measuring the specific absorption at 405 nm versus non-specific absorption at 490 nm in a microplate reader (Dynatech). scFv(FRP5)-DETA-DGAL4 is binding to SK-BR-3 cells with a half maximal saturation value of  $2 \times 10^{-8}$  M.

**Example 13****DNA-transfer experiments****13.1 Calcium-phosphate transfection:**

Calcium phosphate transfections of COS-1 and SK-BR-3 cells are carried out with the pSV2LUC-G4 reporter plasmid described in Example 10. To DNA solutions in water 2.5 M calcium chloride is added to a final concentration of 166 mM calcium chloride. 1 volume of 2x HBS buffer, pH 7.12, containing 50 mM HEPES, 15 mM  $\text{Na}_2\text{HPO}_4$ , and 280 mM sodium chloride, is added dropwise with constant flow of air bubbles through the mixture. The final DNA concentration in the mixture is 10 nM in the experiment with COS-1 cells and 1.9 nM in the experiment with SK-BR-3 cells. Crystals are allowed to form in the solution for 30 min at room temperature. 100 ml of the solution is added to one well of tissue culture cells in 12 well tissue culture plates as described in 13.2, cells are harvested and luciferase units are determined as described in 13.3.

**13.2 Cell culture and DNA transfer:**

SK-BR-3 human breast carcinoma cells (ATCC HTB30) and COS-1 SV40 transformed African Green monkey kidney cells (ATCC CRL1650) are seeded in 12 well tissue culture plates at a density of  $3.6 \times 10^4$  cells/well and grown overnight at 37°C. The tissue culture medium is exchanged with 1 ml/well fresh medium and the cells are grown for another 5 h. 100 ml of the respective sample containing the DNA-transfer mixture described in 13.4, 13.5, 13.6 or 13.7 is added to each well and the cells are incubated at 37°C overnight. The tissue culture medium is replaced with 2 ml/well of fresh medium and the cells are incubated for another 24 h before they are harvested for analysis as described in 13.3.

**13.3 Luciferase assay:**

The medium is removed from the cells and cells are washed twice with PBS. 100 ml of lysis buffer, pH 7.8, containing 25 mM Gly-Gly dipeptide (Sigma), 1 mM DTT, 15 % glycerol, 8 mM magnesium sulphate, 1 mM EDTA, 1 % Triton X100, is added to each well and the cells are incubated for 15 min at room temperature. The lysate is collected and centrifuged for 5 sec in an Eppendorf centrifuge to remove particulate matter. 50 ml of the supernatant is mixed with 50 ml of dilution buffer, pH 7.8, containing 25 mM Gly-Gly dipeptide, 10 mM magnesium sulphate, 5 mM ATP. 300 ml of luciferin solution, pH 7.8, containing 25 mM Gly-Gly dipeptide, 0.5 mM coenzyme A (Boehringer Mannheim), 250 mM luciferin (Sigma), is added to the sample and luciferase activity is determined with a luminometer.

**13.4 scFv(FRP5)-DETA-DGAL4-mediated DNA transfer in COS-1 cells:**

DNA of pSV2LUC-G4 reporter plasmid described in Example 10 is mixed with scFv(FRP5)-DETA-DGAL4 protein at a final concentration of 10 nM (DNA) and 40 nM (protein) in a buffer containing 50 mM HEPES, pH 7.5, 50 mM potassium chloride, 5 mM magnesium chloride and 100 mM zinc chloride. The mixture is incubated for 10 min at room temperature to allow the formation of protein/DNA complexes. Poly-L-lysine (Sigma) is added to the mixture to final concentrations of 100 or 500 nM, respectively, and the mixture is incubated for further 30 min at room temperature. 100 µl of the solution is added to one well of COS-1 cells in 12 well tissue culture plates as described in 13.2 cells are harvested and luciferase units are determined as described in 13.3. Expression of luciferase is detected in cells transfected with the calcium-phosphate transfection method described in 13.1 and cells treated with scFv(FRP5)-DETA-DGAL4/pSV2LUC-G4 complex containing poly-L-lysine, but not in cells treated with pSV2LUC-G4 and poly-L-lysine alone.

**13.5 scFv(FRP5)-DETA-DGAL4-mediated DNA transfer in SK-BR-3 cells:**

A mixture containing DNA of pSV2LUC-G4 reporter plasmid and scFv(FRP5)-DETA-DGAL4 protein is prepared as described in 13.4. The mixture is incubated for 10 min at room temperature to allow the formation of protein/DNA complexes. Poly-L-lysine (Sigma) is added to the mixture to a final concentration of 100 nM and the mixture is incubated for further 30 min at room temperature. 100 µl of the solution is added to one well of SK-BR-3 cells in 12 well tissue culture plates as described in 13.2, cells are harvested and luciferase units are determined as described in 13.3. Expression of luciferase is detected in cells transfected with the calcium-phosphate transfection method described in 13.1 and cells treated with scFv(FRP5)-DETA-DGAL4/pSV2LUC-G4 complex containing poly-L-lysine, but not in cells treated with pSV2LUC-G4 alone or scFv(FRP5)-DETA-DGAL4/pSV2LUC-G4 complex without the addition of poly-L-lysine.

**13.6 Competition assay:**

A mixture containing DNA of pSV2LUC-G4 reporter plasmid and scFv(FRP5)-DETA-DGAL4 protein is prepared as described in 13.4. The mixture is incubated for 10 min at room temperature to allow the formation of protein/DNA complexes. Poly-L-lysine (Sigma) is added to the mixture to a final concentration of 500 nM and the mixture is incubated for further 30 min at room temperature. One sample is prepared containing in addition to pSV2LUC-G4 reporter plasmid, scFv(FRP5)-DETA-DGAL4 and poly-L-lysine the monoclonal antibody FRP5 which has the same binding specificity as scFv(FRP5)-DETA-DGAL4 as a competitor for binding to p185<sup>erbB-2</sup> at a final concentration of 1.2 mM. 100 µl of



the solution is added to one well of COS-1 cells in 12 well tissue culture plates as described in 13.2, cells are harvested and luciferase units are determined as described in 13.3. Expression of luciferase is detected in cells treated with scFv(FRP5)-DETA-DGAL4/pSV2LUC-G4 complex containing poly-L-lysine, but not in cells treated only with pSV2LUC-G4 and poly-L-lysine or scFv(FRP5)-DETA-DGAL4/pSV2LUC-G4 complex containing poly-L-lysine in the presence of an excess of monoclonal antibody FRP5 as competitor.

#### **Example 14**

##### **Isolation of RNA from the breast carcinoma cell line MDA-MB-468**

###### **14.1 Growth of MDA-MB-468 cells:**

MDA-MB-468 breast carcinoma cells (ATCC HTB132) are grown as monolayers on tissue culture plates at 37°C in DMEM (Seromed) further containing 8 % FCS (Amined) and 100 mg/ml of gentamycin (Seromed) in a humidified atmosphere of air and 7.5 % CO<sub>2</sub>. The cells are washed twice with PBS on ice, PBS is removed and the plates are kept on ice.

###### **14.2 Extraction of total cellular RNA from MDA-MB-468 cells:**

Total RNA is extracted using the acid guanidinium thiocyanate-phenol-chloroform method described by Choczynski & Dacchi (Anal. Biochem. 162: 156, 1987). The cells from 2 semi-confluent tissue culture plates are lysed on ice in the presence of 2 ml denaturing solution (see Example 3.2). The lysate is homogenized at room temperature. Sequentially, 0.2 ml of 2 M sodium acetate, pH 4, 2 ml of phenol (water saturated) and 0.4 ml of chloroform-isoamyl alcohol mixture (49:1) are added to the lysate. The final suspension is shaken vigorously for 10 sec and cooled on ice for 15 min. The samples are centrifuged at 10,000 x g for 20 min at 4°C. After centrifugation, RNA which is present in the aqueous phase is mixed with 2 ml of isopropanol and placed at -20°C for 1 h. The RNA precipitate is collected by centrifugation, the pellet dissolved in 0.5 ml water and the RNA precipitated by addition of 1 volume of isopropanol at -20°C. After centrifugation and washing the pellet in ethanol, the final pellet of RNA is dissolved in water. The method yields approximately 100 mg of total cellular RNA. The final purified material is stored frozen at -20°C.

#### **Example 15**

##### **Cloning of a human transforming growth factor- $\alpha$ cDNA fragment**

Total cellular RNA isolated from MDA-M-468 cells as described in Example 14 provides the source for cDNA synthesis and subsequent amplification of a human transforming growth

factor (TGF)- $\alpha$  encoding cDNA fragment. Amplification products of the expected size are purified from agarose gels and cloned into appropriate vectors. Intact cDNA clones are identified by sequencing.

#### **15.1 cDNA synthesis:**

5 mg of total RNA isolated from MDA-MB-468 cells is used in a 33 ml first strand cDNA synthesis reaction with 11 ml Bulk First-Strand Reaction Mix (Pharmacia), 200 ng NotI-d(T)<sub>18</sub> primer (Pharmacia), and 1 ml 200 mM DTT solution according to procedures provided by the manufacturer.

#### **15.2 Polymerase chain reaction:**

2 ml of the cDNA reaction is used for DNA amplification in a 50 ml reaction containing 25 pmol each of the two oligonucleotides complementary to regions in the human TGF- $\alpha$  gene 5'-GACCCGAAGCTTGGTACCGGTGTGGTGTCCCATTTTAATG -3' (SEQ ID NO. 29) and 5'-TTCTGGGAGCTCTCTAGAGAGGCCAGGAGGTCCGC -3' (SEQ ID NO. 30), 4 ml 2.5 mM dNTP (N= G, A, T, C) mixture, and 5 ml 10x Vent DNA polymerase buffer (New England Biolabs) and 2.5 U of Vent DNA polymerase (New England Biolabs). Vent DNA polymerase is added after initial denaturation at 94°C for 4 min. For 30 cycles annealing is performed for 1 min at 52°C, primer extension for 45 sec at 72°C, denaturation for 1 min at 94°C. Finally, amplification is completed by a 2 min primer extension step at 72°C.

#### **15.3 Modification and purification:**

Amplification products are separated on a 1.5 % (w/v) agarose gel (ultra pure agarose, BRL), DNA of the expected size is eluted, and subsequently digested with HindIII and XbaI. The expected 171 bp DNA fragment encoding amino acids 1 to 50 of human TGF- $\alpha$  is separated on a 1.5 % agarose gel and purified by elution from the gel as described above.

#### **15.4 Ligation:**

Plasmid pFLAG-1 is digested with SalI, and treated with the Klenow enzyme to create blunt ends; the linearized fragment is digested with XbaI. A truncated Pseudomonas ETA gene lacking the cell-binding domain Ia is isolated from pWW20 (see Example 1.1) by EcoRI cleavage, Klenow fill-in and Subsequent XbaI digestion. This blunt-ended XbaI fragment is inserted into the blunt-ended XbaI pFLAG-1 vector. The resulting plasmid, pSG100, is digested with HindIII and XbaI and a double stranded DNA linker encoding 6 histidine residues is inserted in frame 5' of the ETA sequences yielding pSW200. A DNA fragment containing the ompA signal peptide, the FLAG epitope and the N-terminal histidine-encoding

sequences is isolated by NdeI and XbaI digestion of pSW50 (see Example 8.2) and inserted into NdeI/XbaI digested pSW200. The resulting plasmid is designated pSW202. pSW202 (50 ng) digested with HindIII and XbaI, and 30 ng of purified amplification product are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., supra). The following plasmid is obtained: pSW202-TGF. The partial DNA sequence of pSW202-TGF is shown in SEQ ID NO. 31. Said sequence has the following features:

from 1 to 15 bp	synthetic spacer
from 16 to 165 bp	encoding amino acids 1 to 50 of human TGF- $\alpha$
from 166 to 173 bp	synthetic spacer

#### Example 16

##### Construction of the TGF- $\alpha$ -DETA-DGAL4 fusion gene

###### 16.1 Derivation of DNA fragments and purification:

pSW202-TGF (1 mg) is digested with HindIII and SalI. DNA fragments are separated on a 1.0% (w/v) agarose gel (ultra pure agarose, BRL) and the expected bp HindIII/SalI DNA fragment carrying the TGF- $\alpha$ -DETA<sub>252-308</sub> fusion gene is eluted. Plasmid pWF45-5 (1 mg) is digested with SalI and XbaI. DNA fragments are separated and the expected 655bp SalI/XbaI DNA fragment encoding DETA<sub>309-366</sub>-DGAL4 is eluted as described above. pWF45-5 (1 mg) is digested with HindIII and XbaI. DNA fragments are separated and the expected HindIII/XbaI vector fragment is eluted as described above.

###### 16.2 Ligation:

50 ng of purified HindIII/XbaI pWF45-5 vector fragment, and 30 ng of purified HindIII/SalI TGF- $\alpha$ -DETA fragment, and 30 ng of purified Sal/XbaI DETA-DGAL4 fragment are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method. The following plasmid is obtained: pWF47-TGF. The partial DNA

sequence f pWF47-TGF encodes TGF-a-DETA-DGAL4 fusion protein is shown in SEQ ID NO. 3. Said sequence has the following features:

1 to 63 bp	encoding the E.coli ompA signal peptide
64 to 87 bp	encoding the synthetic FLAG epitope
88 to 99 bp	spacer sequence
100 to 249 bp	encoding amino acids 1 to 50 of human TGF-a
259 to 276 bp	encoding 6 His residues
277 to 279 bp	synthetic spacer sequence
280 to 624 bp	encoding amino acid 252 to 366 of ETA
625 to 627 bp	spacer
628 to 1065 bp	encoding aa 2 to 147 of yeast GAL4
1066 to 1089 bp	spacer including sequence coding for KDEL retention signal.

The partial deduced amino acid sequence of the pWF47-TGF encoded TGF-a-DETA-D GAL4 protein including a peptide spacer at the N-terminus (aa 1 to 12) is shown in SEQ ID NO.4.

#### **Example 17**

##### **Bacterial expression and purification of TGF-a-DETA-D GAL4**

A translocation domain derivable from *P. aeruginosa* exotoxin A (ETA), particularly a domain consisting essentially of domain II of ETA (amino acids 253 to 364 of ETA as set forth in Gray et al., Proc. Natl. Acad. Sci. USA 81: 2645, 1984), e.g. a translocation domain consisting of amino acids 252 to 366 of ETA is described in Examples 17 and 18 in conjunction with SEQ ID NOs. 1, 3 and 5.

Plasmid pWF47-TGF is transformed into *E.coli* K12 (Manoil & Beckwith, Proc. Natl. Acad. Sci. USA 82: 8129, 1985). Expression and purification of TGF-a-DETA-D GAL4 is carried out as described in Example 9. for the expression and purification of scFv(FRP5)-DETA-D GAL4.

**Example 18****Construction of an interleukin-2-DETA-DGAL4 fusion gene****18.1 Polymerase chain reaction:**

20 ng of a pBR322 derivative carrying a human interleukin (IL)-2 cDNA insert (Taniguchi et al., Nature 302: 305, 1983) is used for DNA amplification in a 50 ml reaction containing 25 pmol each of the two oligonucleotides complementary to regions in the human IL-2 gene 5'-TATAATAAGCTTGCACCTACTTCAAG -3' (SEQ ID NO. 32) and 5'-TTGAATGCTAGCGTTAGTGTTGAGATG -3' (SEQ ID NO. 33), 4 ml 2.5 mM dNTP (N= G, A, T, C) mixture, and 5 ml 10x Vent DNA polymerase buffer (New England Biolabs) and 2.5 U of Vent DNA polymerase (New England Biolabs). Vent DNA polymerase is added after initial denaturation at 94°C for 4 min. For 30 cycles annealing is performed for 1 min at 50°C, primer extension for 45 sec at 72°C, denaturation for 1 min at 94°C. Finally, amplification is completed by a 2 min primer extension step at 72°C.

**18.2 Modification and purification:**

Amplification products are separated on a 1.5 % (w/v) agarose gel (ultra pure agarose, BRL), DNA of the expected size is eluted, and subsequently digested with HindIII and NheI. The expected 408 bp DNA fragment encoding amino acids 1 to 113 of human IL-2 is separated on a 1.5 % agarose gel and purified by elution from the gel as described above.

**18.3 Derivation of DNA fragments and purification:**

pWF46-5 (1 mg) (see Example 8.) is digested with XbaI and EcoRI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 821 bp XbaI/EcoRI DNA fragment carrying the DETA-DGAL4 coding region is eluted. In a separate digestion pWF46-5 (1 mg) is digested with HindIII and EcoRI. DNA fragments are separated and the expected 5.4 kb HindIII/EcoRI vector fragment is eluted as described above.

**18.4 Ligation:**

pWF46-5 HindIII/EcoRI vector fragment (50 ng), 30 ng of purified HindIII/NheI IL-2 cDNA fragment, and 30 ng of purified XbaI/EcoRI DETA-DGAL4 fragment are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method.

The following plasmid is obtained: pWF46-IL-2. The partial DNA sequence of pWF46-IL-2 is shown in SEQ ID NO. 5.

Said sequence has the following features:

1 to 63 bp	encoding the E.coli ompA signal peptide
64 to 87 bp	encoding the FLAG epitope
88 to 114 bp	spacer sequence
109 to 114 bp	spacer sequence
115 to 513 bp	encoding human IL-2 amino acids 1 to 113
514 to 516 bp	spacer sequence
517 to 861 bp	encoding amino acid 252 to 366 of ETA
862 to 865 bp	spacer
866 to 1302 bp	encoding aa 2 to 147 of yeast GAL4
1303 to 1326 bp	spacer including sequence coding for KDEL retention signal
1327 to 1329 bp	ochre stop codon

The partial deduced amino acid sequence of the pWF46-IL-2 encoded IL-2-DETA-D GAL4 protein including an N-terminal peptide spacer (aa is shown in SEQ ID NO. 6).

#### **18.5 Bacterial expression and purification of IL-2-DETA-D GAL4:**

Plasmid pWF46-IL-2 is transformed into E.coli CC118 (Manoil & Beckwith, Proc. Natl. Acad. Sci. USA 82: 8129, 1985). Expression and purification of IL-2-DETA-D GAL4 is carried out as described in Example 8. for the expression and purification of scFv(FRP5)-DETA-D GAL4.

#### **Deposition Data:**

E. coli XL 1 Blue/pWF47-TGF was deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig on October 24, 1994 under the accession number DSM 9513.

**Example 19****Construction of plasmid pSW50-GD5**

A plasmid for the bacterial expression of a fusion protein consisting of the ompA signal peptide,  $\Delta$ GAL4, a fragment spanning amino acids Val196 to Gly384 of the diphtheria toxin (DT) B fragment (translocation domain), the scFv(FRP5) single chain antibody domain and adjacent linker sequences is constructed.

**19.1 Deletion of scFv(FRP5) and  $\Delta$ ETA domains from plasmid pWF46-5:**

pWF46-5 (1  $\mu$ g) is digested with HindIII. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the DNA fragment consisting of the pSW50 vector and the  $\Delta$ GAL4 fragment is eluted as described above. The eluted fragment is subsequently ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E.coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pSW50-G.

**19.2 Insertion of a linker sequence:**

A double stranded DNA adaptor with SacI and Sall compatible ends and containing an internal NheI restriction site is constructed by annealing 0.5 nmol of the oligonucleotide 5'-CGCTAGCTGGTGGTG -3' (SEQ ID NO:50) with 0.5 nmol of the oligonucleotide 5'-TCGACACCACCAGCTAGCGAGCT -3' (SEQ ID NO:51) by incubation at 65°C for 3 min and cooling to room temperature. pSW50-G (1  $\mu$ g) is digested with SacI and Sall. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the DNA fragment consisting of the pSW50 vector and the  $\Delta$ GAL4 fragment is eluted as described above. The eluted fragment (50 ng) and 20 pmol SacI/Sall oligonucleotide adaptor are subsequently ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E.coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pSW50-G/NheI.

### 19.3 Isolation of the Diphtheria toxin gene fragment encoding the translocation domain ( $\Delta$ DT):

A plasmid (pJV127) which contains the diphtheria toxin - interleukin-2 fusion gene fragment encoding DAB389-IL-2 (Williams et al., J. Biol. Chem. 265: 11885-11889, 1990) is used as a template in a polymerase chain reaction to amplify a DNA fragment comprising amino acids Val196 to Gly384 of the diphtheria toxin (DT) B fragment (translocation domain), designated  $\Delta$ DT.

50 ng of pJV127 is used for DNA amplification in a 50  $\mu$ l reaction containing 50 pmol each of the two oligonucleotides complementary to regions in the diphtheria toxin gene 5'-CGTGTCAGGCTAGCAGTAGGTAGC -3' (SEQ ID NO:52) and 5'-CATGCGTGTCGACACCCGGAGAGTAAGC -3' (SEQ ID NO:53), 4  $\mu$ l 2.5 mM dNTP (N= G, A, T, C) mixture, 5  $\mu$ l 10x Taq DNA polymerase buffer (Boehringer Mannheim) and 2.5 U of Taq DNA polymerase (Boehringer Mannheim). Taq DNA polymerase is added after initial denaturation at 94°C for 2 min. For 30 cycles annealing is performed for 1 min at 55°C, primer extension for 1 min at 72°C, denaturation for 1 min at 94°C. Finally, amplification is completed by a 3 min primer extension step at 72°C.

Amplification products are separated on a 1.2 % (w/v) agarose gel (ultra pure agarose, BRL), DNA of the expected size is eluted as described above, and subsequently digested with NheI and SalI. The expected 575 bp diphtheria toxin DNA fragment encoding the translocation domain and adjacent synthetic linker sequences is separated on a 1.2 % agarose gel and purified by elution from the gel as described above.

### 19.4 Ligation:

pSW50-G/NheI (50 ng) digested with NheI and SalI, and 30 ng of purified amplification product are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pSW50-GD.



**19.5 Derivation of scFv(FRP5) DNA fragment and ligation of pSW50-GD5:**

pWW152-5 (1 µg) carrying the gene encoding the ErbB-2 specific single chain Fv (scFv) molecule scFv(FRP5) described by Wels et al., Int. J. Cancer 60: 137-144, 1995, is digested with Sall and BamHI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 756 bp Sall/BamHI DNA fragment carrying the scFv(FRP5) domain and adjacent synthetic sequences is eluted as described above. pSW50-GD (50 ng) digested with Sall and BglII and scFv(FRP5) Sall/BamHI (50 ng) DNA fragments are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E.coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pSW50-GD5. The partial DNA sequence of pSW50-GD5 is shown in SEQ ID NO. 34. Said sequence has the following features:

from 1 to 63 bp	encoding the <i>E.coli</i> ompA signal peptide
from 64 to 87 bp	encoding the synthetic FLAG epitope
from 88 to 108 bp	synthetic spacer sequence
from 109 to 546 bp	encoding amino acids 2 to 147 of yeast GAL4
from 547 to 558 bp	synthetic spacer sequence
from 559 to 1125 bp	encoding amino acids Val196 to Gly384 of diphtheria toxin
from 1126 to 1146 bp	synthetic spacer sequence
from 1147 to 1866 bp	encoding scFv(FRP5)
from 1867 to 1908 bp	synthetic spacer sequence
from 1909 to 1911 bp	stop codon
from 1912 to 1919 bp	non-coding synthetic spacer

The deduced amino acid sequence of the pSW50-GD5 encoded ΔGAL4-ΔDT-scFv(FRP5) (=GD5) protein including a peptide spacer at the N-terminus (aa 1 to 15) is shown in SEQ ID NO. 35.

**Example 20****Construction of plasmid pSW55-GD5**

A plasmid for the bacterial expression of a fusion protein consisting of  $\Delta$ GAL4, a fragment spanning amino acids Val196 to Gly384 of the diphtheria toxin (DT) B fragment (translocation domain), the scFv(FRP5) single chain antibody domain and adjacent linker sequences is constructed.

**20.1 Insertion of a linker sequence:**

A double stranded DNA adaptor with NdeI and HindIII compatible ends is constructed by annealing 0.5 nmol of the oligonucleotide

5'-TATGGACTACAAGGACGACGATGACAAGAAGCTGCACCATCATCACCATCACA  
-3' (SEQ ID NO:54) with 0.5 nmol of the oligonucleotide  
5'-AGCTTGTGATGGTGTGATGATGGTGCAGCTTCTTGTCATCGTCGTCCTTGTAGTCCA  
-3' (SEQ ID NO:55) by incubation at 65°C for 3 min and cooling to room temperature.

pSW50 (1  $\mu$ g) is digested with NdeI and HindIII. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the pSW50 vector DNA fragment is eluted as described above. The eluted fragment (50 ng) and 20 pmol NdeI/HindIII oligonucleotide adaptor are subsequently ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pSW55.

**20.2 Derivation of DNA fragments and ligation:**

pSW50-GD5 (1  $\mu$ g) is digested with HindIII and KpnI and in a separate reaction with KpnI and XhoI. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 673 bp HindIII/KpnI DNA fragment carrying the  $\Delta$ GAL4 domain, the 5' part of the  $\Delta$ DT domain and adjacent synthetic sequences, and the 1106 bp KpnI/XhoI fragment carrying the 3' part of the  $\Delta$ DT domain, the scFv(FRP5) domain and adjacent synthetic sequences are eluted as described above. pSW55 (50 ng) digested with HindIII and XhoI, and the HindIII/KpnI and KpnI/XhoI (50 ng each) DNA fragments are ligated using 0.5

U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E. coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pSW55-GD5. The partial DNA sequence of pSW55-GD5 is shown in SEQ ID NO. 36. Said sequence has the following features:

from 1 to 3 bp	synthetic spacer sequence
from 4 to 27 bp	encoding the synthetic FLAG epitope
from 28 to 51 bp	synthetic spacer sequence
from 52 to 489 bp	encoding amino acids 2 to 147 of yeast GAL4
from 490 to 501 bp	synthetic spacer sequence
from 502 to 1068 bp	encoding amino acids Val196 to Gly384 of diphtheria toxin
from 1069 to 1089 bp	synthetic spacer sequence
from 1090 to 1809 bp	encoding scFv(FRP5)
from 1810 to 1851 bp	synthetic spacer sequence
from 1852 to 1854 bp	stop codon
from 1855 to 1862 bp	non-coding synthetic spacer

The deduced amino acid sequence of the pSW55-GD5 encoded  $\Delta$ GAL4- $\Delta$ DT-scFv(FRP5) (=GD5) protein including a peptide spacer at the N-terminus (aa 1 to 17) is shown in SEQ ID NO. 37.

#### Example 21

##### Construction of plasmid pSW50-GDI

A plasmid for the bacterial expression of a fusion protein consisting of the ompA signal peptide,  $\Delta$ GAL4, a fragment spanning amino acids Val196 to Gly384 of the diphtheria toxin (DT) B fragment (translocation domain), the human interleukin-2 (IL-2) domain and adjacent linker sequences is constructed.

**21.1 Construction of plasmid pWW152-IL-2:**

Plasmid pSW50-IL-2 (1 µg) is digested with EcoRI. The linearized DNA is treated with DNA polymerase I (Klenow fragment) (Boehringer Mannheim) to create blunt ends (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989) and subsequently digested with HindIII. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the expected 418 bp HindIII/blunt ended DNA fragment carrying the IL-2 domain and adjacent synthetic sequences is eluted as described above. Plasmid pWW152 digested with HindIII and PvuII (50 ng) and the HindIII/blunt ended IL-2 DNA fragment are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E.coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pWW152-IL-2.

**21.2 Derivation of DNA fragments and ligation:**

pWW152-IL-2 (1 µg) is digested with SalI and BglII. DNA fragments are separated on a 1.0 % (w/v) agarose gel (ultra pure agarose, BRL) and the SalI/BglII DNA fragment carrying the IL-2 domain and adjacent synthetic sequences is eluted as described above. pSW50-GD (50 ng) digested with SalI and BglII and IL-2 SalI/BglII (50 ng) DNA fragments are ligated using 0.5 U T4 DNA ligase (New England Biolabs) in 50 mM Tris-HCl, pH 7.8, 10 mM magnesium chloride, 10 mM DTT, and 0.8 mM ATP overnight at 16°C. One half of ligation mixture is used to transform *E.coli* XL1 Blue (Stratagene) to obtain ampicillin resistant colonies. These are screened for the desired ligation product using a NaOH based plasmid "miniprep" method (Maniatis et al., Molecular Cloning: A Laboratory Manual / Second Edition, Cold Spring Harbor Laboratory, 1989). The following plasmid is obtained: pSW50-GDI. The partial DNA sequence of pSW50-GDI is shown in SEQ ID NO. 38. Said sequence has the following features:

from 1 to 63 bp	encoding the E.coli ompA signal peptide
from 64 to 87 bp	encoding the synthetic FLAG epitope
from 88 to 108 bp	synthetic spacer sequence
from 109 to 546 bp	encoding amino acids 2 to 147 of yeast GAL4
from 547 to 558 bp	synthetic spacer sequence

- 55 -

from 559 to 1125 bp	encoding amino acids Val196 to Gly384 of diphtheria toxin
from 1126 to 1152 bp	synthetic spacer sequence
from 1153 to 1551 bp	encoding human IL-2 amino acids 1 to 113
from 1552 to 1554 bp	stop codon
from 1555 to 1605 bp	non-coding synthetic spacer

The deduced amino acid sequence of the pSW50-GDI encoded  $\Delta$ GAL4- $\Delta$ DT-IL-2 (=GDI) protein including a peptide spacer at the N-terminus (aa 1 to 15) is shown in SEQ ID NO. 39.

#### Example 22

##### Bacterial expression and purification of GD5

Plasmids pSW50-GD5 or pSW55-GD5 are transformed into E.coli K12. Expression and purification of  $\Delta$ GAL4- $\Delta$ DT-scFv(FRP5) protein GD5 is carried out as described in Example 9. for the expression and purification of scFv(FRP5)- $\Delta$ ETA- $\Delta$  GAL4.

#### Example 23

##### GD5-mediated DNA transfer in COS-1 cells

COS-1 cells are seeded in 12 well tissue culture plates as described in Example 13.2. DNA of pSV2LUC-G4 reporter plasmid described in Example 10 is mixed with the GD5 protein at a final concentration of 10 nM (DNA) and 40 nM (protein) using the buffer and incubation conditions described in 13.4. Poly-L-lysine (Sigma) is added to the mixture as described in 13.4 and the complex is added to COS-1 cells as described in 13.2. The cells are harvested and luciferase units are determined as described in 13.3. Expression of luciferase is detected in cells treated with GD5/pSV2LUC-G4 complex containing poly-L-lysine, but not in cells treated with pSV2LUC-G4 and poly-L-lysine alone.

- 56 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: WELS, Winfried, Dr.
- (B) STREET: Glimpenheimer Str. 55
- (C) CITY: Emmendingen
- (E) COUNTRY: Germany
- (F) POSTAL CODE (ZIP): D-79312
- (G) TELEPHONE: 0761-206-1630
- (H) TELEFAX: 0761-206-1599

(ii) TITLE OF INVENTION: Nucleic Acid Transfer System

(iii) NUMBER OF SEQUENCES: 55

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1692 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: pWF46-5

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 1..63
- (D) OTHER INFORMATION: /product= "E. coli OmpA signal peptide"

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 64..1656
- (D) OTHER INFORMATION: /product= "scFv(FRP5)-delta ETA-delta GAL4"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATGAAAAAGA CAGCTATCGC GATTGCAGTG GCACTGGCTG GTTTCGCTAC CGTTGCGCAA 60

- 57 -

GCT	GAC	TAC	AAG	GAC	GAC	GAT	GAC	AAG	CTG	CAC	CAT	CAT	CAC	CAT	CAC	108
Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Asp	Lys	Leu	His	His	His	His	His	His	
1				5					10						15	
AAG	CTT	CAG	GTA	CAA	CTG	CAG	CAG	TCT	GGA	CCT	GAA	CTG	AAG	AAG	CCT	156
Lys	Leu	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Lys	Lys	Pro	
			20						25					30		
GGA	GAG	ACA	GTC	AAG	ATC	TCC	TGC	AAG	GCC	TCT	GGG	TAT	CCT	TTC	ACA	204
Gly	Glu	Thr	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Pro	Phe	Thr	
			35					40					45			
AAC	TAT	GGA	ATG	AAC	TGG	GTG	AAG	CAG	GCT	CCA	GGA	CAG	GGT	TTA	AAG	252
Asn	Tyr	Gly	Met	Asn	Trp	Val	Lys	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Lys	
		50					55					60				
TGG	ATG	GGC	TGG	ATT	AAC	ACC	TCC	ACT	GGA	GAG	TCA	ACA	TTT	GCT	GAT	300
Trp	Met	Gly	Trp	Ile	Asn	Thr	Ser	Thr	Gly	Glu	Ser	Thr	Phe	Ala	Asp	
	65					70					75					
GAC	TTC	AAG	GGA	CGG	TTT	GAC	TTC	TCT	TTG	GAA	ACC	TCT	GCC	AAC	ACT	348
Asp	Phe	Lys	Gly	Arg	Phe	Asp	Phe	Ser	Leu	Glu	Thr	Ser	Ala	Asn	Thr	
80					85				90						95	
GCC	TAT	TTG	CAG	ATC	AAC	AAC	CTC	AAA	AGT	GAA	GAC	ATG	GCT	ACA	TAT	396
Ala	Tyr	Leu	Gln	Ile	Asn	Asn	Leu	Lys	Ser	Glu	Asp	Met	Ala	Thr	Tyr	
			100					105						110		
TTC	TGT	GCA	AGA	TGG	GAG	GTT	TAC	CAC	GGC	TAC	GTT	CCT	TAC	TGG	GGC	444
Phe	Cys	Ala	Arg	Trp	Glu	Val	Tyr	His	Gly	Tyr	Val	Pro	Tyr	Trp	Gly	
			115					120					125			
CAA	GGG	ACC	ACG	GTC	ACC	GTT	TCC	TCT	GGC	GGT	GGC	GGT	TCT	GGT	GGC	492
Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	
		130					135					140				
GGT	GGC	TCC	GGC	GGT	GGC	GGT	TCT	GAC	ATC	CAG	CTG	ACC	CAG	TCT	CAC	540
Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Ile	Gln	Leu	Thr	Gln	Ser	His	
	145					150					155					
AAA	TTC	CTG	TCC	ACT	TCA	GTA	GGA	GAC	AGG	GTC	AGC	ATC	ACC	TGC	AAG	588
Lys	Phe	Leu	Ser	Thr	Ser	Val	Gly	Asp	Arg	Val	Ser	Ile	Thr	Cys	Lys	
160					165				170						175	
GCC	AGT	CAG	GAT	GTG	TAT	AAT	GCT	GTT	GCC	TGG	TAT	CAA	CAG	AAA	CCA	636
Ala	Ser	Gln	Asp	Val	Tyr	Asn	Ala	Val	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	
			180						185					190		
GGA	CAA	TCT	CCT	AAA	CTT	CTG	ATT	TAC	TCG	GCA	TCC	TCC	CGG	TAC	ACT	684
Gly	Gln	Ser	Pro	Lys	Leu	Leu	Ile	Tyr	Ser	Ala	Ser	Ser	Arg	Tyr	Thr	
			195					200					205			
GGA	GTC	CCT	TCT	CGC	TTC	ACT	GGC	AGT	GGC	TCT	GGG	CCG	GAT	TTC	ACT	732
Gly	Val	Pro	Ser	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Pro	Asp	Phe	Thr	
	210						215					220				

TTC ACC ATC AGC AGT GTG CAG GCT GAA GAC CTG GCA GTT TAT TTC TGT	780
Phe Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys	
225 230 235	
CAG CAA CAT TTT CGT ACT CCA TTC ACG TTC GGC TCG GGG ACA AAA TTG	828
Gln Gln His Phe Arg Thr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu	
240 245 250 255	
GAG ATC AAA GCT CTA GAG GGC GGC AGC CTG GCC GCG CTG ACC GCG CAC	876
Glu Ile Lys Ala Leu Glu Gly Gly Ser Leu Ala Ala Leu Thr Ala His	
260 265 270	
CAG GCC TGC CAC CTG CCG CTG GAG ACT TTC ACC CGT CAT CGC CAG CCG	924
Gln Ala Cys His Leu Pro Leu Glu Thr Phe Thr Arg His Arg Gln Pro	
275 280 285	
CGC GGC TGG GAA CAA CTG GAG CAG TGC GGC TAT CCG GTG CAG CGG CTG	972
Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu	
290 295 300	
GTC GCC CTC TAC CTG GCG GCG CGA CTG TCA TGG AAC CAG GTC GAC CAG	1020
Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp Asn Gln Val Asp Gln	
305 310 315	
GTG ATC CGC AAC GCC CTG GCC AGC CCC GGC AGC GGC GGC GAC CTG GGC	1068
Val Ile Arg Asn Ala Leu Ala Ser Pro Gly Ser Gly Gly Asp Leu Gly	
320 325 330 335	
GAA GCG ATC CGC GAG CAG CCG GAG CAG GCC CGT CTG GCC CTG ACC CTG	1116
Glu Ala Ile Arg Glu Gln Pro Glu Gln Ala Arg Leu Ala Leu Thr Leu	
340 345 350	
GCC GCC GCC GAG AGC GAG CCG TTC GTC CGG CAG GGC ACC GGC AAC GAC	1164
Ala Ala Ala Glu Ser Glu Arg Phe Val Arg Gln Gly Thr Gly Asn Asp	
355 360 365	
GAG GCC GGC GCG GCC AAC GCC GAC GAG AAG CTT CTG TCT TCT ATC GAA	1212
Glu Ala Gly Ala Ala Asn Ala Asp Glu Lys Leu Leu Ser Ser Ile Glu	
370 375 380	
CAA GCA TGC GAT ATT TGC CGA CTT AAA AAG CTC AAG TGC TCC AAA GAA	1260
Gln Ala Cys Asp Ile Cys Arg Leu Lys Lys Leu Lys Cys Ser Lys Glu	
385 390 395	
AAA CCG AAG TGC GCG AAG TGT CTG AAG AAC AAC TGG GAG TGT CGC TAC	1308
Lys Pro Lys Cys Ala Lys Cys Leu Lys Asn Asn Trp Glu Cys Arg Tyr	
400 405 410 415	
TCT CCC AAA ACC AAA AGG TCT CCG CTG ACT AGG GCA CAT CTG ACA GAA	1356
Ser Pro Lys Thr Lys Arg Ser Pro Leu Thr Arg Ala His Leu Thr Glu	
420 425 430	



- 59 -

GTG GAA TCA AGG CTA GAA AGA CTG GAA CAG CTA TTT CTA CTG ATT TTT	1404
Val Glu Ser Arg Leu Glu Arg Leu Glu Gln Leu Phe Leu Leu Ile Phe	
435 440 445	
CCT CGA GAA GAC CTT GAC ATG ATT TTG AAA ATG GAT TCT TTA CAG GAT	1452
Pro Arg Glu Asp Leu Asp Met Ile Leu Lys Met Asp Ser Leu Gln Asp	
450 455 460	
ATA AAA GCA TTG TTA ACA GGA TTA TTT GTA CAA GAT AAT GTG AAT AAA	1500
Ile Lys Ala Leu Leu Thr Gly Leu Phe Val Gln Asp Asn Val Asn Lys	
465 470 475	
GAT GCC GTC ACA GAT AGA TTG GCT TCA GTG GAG ACT GAT ATG CCT CTA	1548
Asp Ala Val Thr Asp Arg Leu Ala Ser Val Glu Thr Asp Met Pro Leu	
480 485 490 495	
ACA TTG AGA CAG CAT AGA ATA AGT GCG ACA TCA TCA TCG GAA GAG AGT	1596
Thr Leu Arg Gln His Arg Ile Ser Ala Thr Ser Ser Ser Glu Glu Ser	
500 505 510	
AGT AAC AAA GGT CAA AGA CAG TTG ACT GTA TCG AGC TCT GAC TAC AAA	1644
Ser Asn Lys Gly Gln Arg Gln Leu Thr Val Ser Ser Ser Asp Tyr Lys	
515 520 525	
GAC GAA CTT TAAGAATTCT CTAGAGATAT CGTCGACAGA TCTCTCGAG	1692
Asp Glu Leu	
530	

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 530 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Asp Tyr Lys Asp Asp Asp Asp Lys Leu His His His His His Lys	
1 5 10 15	
Leu Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly	
20 25 30	
Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Asn	
35 40 45	
Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Lys Trp	
50 55 60	
Met Gly Trp Ile Asn Thr Ser Thr Gly Glu Ser Thr Phe Ala Asp Asp	
65 70 75 80	

- 60 -

Phe Lys Gly Arg Phe Asp Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala  
                                     85                                    90                                    95  
 Tyr Leu Gln Ile Asn Asn Leu Lys Ser Glu Asp Met Ala Thr Tyr Phe  
                                     100                                    105                                    110  
 Cys Ala Arg Trp Glu Val Tyr His Gly Tyr Val Pro Tyr Trp Gly Gln  
                                     115                                    120                                    125  
 Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly  
                                     130                                    135                                    140  
 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser His Lys  
                                     145                                    150                                    155                                    160  
 Phe Leu Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala  
                                     165                                    170                                    175  
 Ser Gln Asp Val Tyr Asn Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly  
                                     180                                    185                                    190  
 Gln Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Thr Gly  
                                     195                                    200                                    205  
 Val Pro Ser Arg Phe Thr Gly Ser Gly Ser Gly Pro Asp Phe Thr Phe  
                                     210                                    215                                    220  
 Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln  
                                     225                                    230                                    235                                    240  
 Gln His Phe Arg Thr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu  
                                     245                                    250                                    255  
 Ile Lys Ala Leu Glu Gly Gly Ser Leu Ala Ala Leu Thr Ala His Gln  
                                     260                                    265                                    270  
 Ala Cys His Leu Pro Leu Glu Thr Phe Thr Arg His Arg Gln Pro Arg  
                                     275                                    280                                    285  
 Gly Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu Val  
                                     290                                    295                                    300  
 Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp Asn Gln Val Asp Gln Val  
                                     305                                    310                                    315                                    320  
 Ile Arg Asn Ala Leu Ala Ser Pro Gly Ser Gly Gly Asp Leu Gly Glu  
                                     325                                    330                                    335  
 Ala Ile Arg Glu Gln Pro Glu Gln Ala Arg Leu Ala Leu Thr Leu Ala  
                                     340                                    345                                    350  
 Ala Ala Glu Ser Glu Arg Phe Val Arg Gln Gly Thr Gly Asn Asp Glu  
                                     355                                    360                                    365  
 Ala Gly Ala Ala Asn Ala Asp Glu Lys Leu Leu Ser Ser Ile Glu Gln

- 61 -

370	375	380
Ala Cys Asp Ile Cys Arg Leu Lys Lys Leu Lys Cys Ser Lys Glu Lys		
385	390	395 400
Pro Lys Cys Ala Lys Cys Leu Lys Asn Asn Trp Glu Cys Arg Tyr Ser		
	405	410 415
Pro Lys Thr Lys Arg Ser Pro Leu Thr Arg Ala His Leu Thr Glu Val		
	420	425 430
Glu Ser Arg Leu Glu Arg Leu Glu Gln Leu Phe Leu Leu Ile Phe Pro		
	435	440 445
Arg Glu Asp Leu Asp Met Ile Leu Lys Met Asp Ser Leu Gln Asp Ile		
	450	455 460
Lys Ala Leu Leu Thr Gly Leu Phe Val Gln Asp Asn Val Asn Lys Asp		
465	470	475 480
Ala Val Thr Asp Arg Leu Ala Ser Val Glu Thr Asp Met Pro Leu Thr		
	485	490 495
Leu Arg Gln His Arg Ile Ser Ala Thr Ser Ser Ser Glu Glu Ser Ser		
	500	505 510
Asn Lys Gly Gln Arg Gln Leu Thr Val Ser Ser Ser Asp Tyr Lys Asp		
	515	520 525
Glu Leu		
530		

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1128 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: pWF47-TGF

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 64..1092
- (D) OTHER INFORMATION: /partial  
/product= "TGF-alpha-delta ETA-delta GAL4 fusion protein"

- 62 -

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 1..63

(D) OTHER INFORMATION: /product= "E. coli OmpA signal peptide"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```

ATGAAAAAGA CAGCTATCGC GATTGCAGTG GCACTGGCTG GTTTCGCTAC CGTTGCGCAA      60
GCT GAC TAC AAG GAC GAC GAT GAC AAG CTT GGT ACC GGT GTG GTG TCC      108
  Asp Tyr Lys Asp Asp Asp Asp Lys Leu Gly Thr Gly Val Val Ser
    1          5          10          15
CAT TTT AAT GAC TGC CCA GAT TCC CAC ACT CAG TTC TGC TTT CAT GGA      156
  His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys Phe His Gly
                20          25          30
ACC TGC AGG TTT TTG GTG CAG GAG GAC AAG CCA GCA TGT GTC TGC CAT      204
  Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys Val Cys His
                35          40          45
TCT GGG TAC GTT GGT GCA CGC TGT GAG CAT GCG GAC CTC CTG GCC TCT      252
  Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu Leu Ala Ser
                50          55          60
CTA GAG CAC CAT CAT CAC CAT CAC CTA GAG GGC GGC AGC CTG GCC GCG      300
  Leu Glu His His His His His His Leu Glu Gly Gly Ser Leu Ala Ala
    65          70          75
CTG ACC GCG CAC CAG GCC TGC CAC CTG CCG CTG GAG ACT TTC ACC CGT      348
  Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu Thr Phe Thr Arg
    80          85          90          95
CAT CGC CAG CCG CGC GGC TGG GAA CAA CTG GAG CAG TGC GGC TAT CCG      396
  His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro
                100          105          110
GTG CAG CGG CTG GTC GCC CTC TAC CTG GCG GCG CGA CTG TCA TGG AAC      444
  Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp Asn
                115          120          125
CAG GTC GAC CAG GTG ATC CGC AAC GCC CTG GCC AGC CCC GGC AGC GGC      492
  Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser Pro Gly Ser Gly
                130          135          140
GGC GAC CTG GGC GAA GCG ATC CGC GAG CAG CCG GAG CAG GCC CGT CTG      540
  Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu Gln Ala Arg Leu
    145          150          155
GCC CTG ACC CTG GCC GCC GCC GAG AGC GAG CGC TTC GTC CGG CAG GGC      588
  Ala Leu Thr Leu Ala Ala Ala Glu Ser Glu Arg Phe Val Arg Gln Gly
    160          165          170          175

```

- 63 -

ACC GGC AAC GAC GAG GCC GGC GCG GCC AAC GCC GAC GAG AAG CTT CTG	636
Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp Glu Lys Leu Leu	
180 185 190	
TCT TCT ATC GAA CAA GCA TGC GAT ATT TGC CGA CTT AAA AAG CTC AAG	684
Ser Ser Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu Lys Lys Leu Lys	
195 200 205	
TGC TCC AAA GAA AAA CCG AAG TGC GCC AAG TGT CTG AAG AAC AAC TGG	732
Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys Asn Asn Trp	
210 215 220	
GAG TGT CGC TAC TCT CCC AAA ACC AAA AGG TCT CCG CTG ACT AGG GCA	780
Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu Thr Arg Ala	
225 230 235	
CAT CTG ACA GAA GTG GAA TCA AGG CTA GAA AGA CTG GAA CAG CTA TTT	828
His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu Gln Leu Phe	
240 245 250 255	
CTA CTG ATT TTT CCT CGA GAA GAC CTT GAC ATG ATT TTG AAA ATG GAT	876
Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu Lys Met Asp	
260 265 270	
TCT TTA CAG GAT ATA AAA GCA TTG TTA ACA GGA TTA TTT GTA CAA GAT	924
Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe Val Gln Asp	
275 280 285	
AAT GTG AAT AAA GAT GCC GTC ACA GAT AGA TTG GCT TCA GTG GAG ACT	972
Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser Val Glu Thr	
290 295 300	
GAT ATG CCT CTA ACA TTG AGA CAG CAT AGA ATA AGT GCG ACA TCA TCA	1020
Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala Thr Ser Ser	
305 310 315	
TCG GAA GAG AGT AGT AAC AAA GGT CAA AGA CAG TTG ACT GTA TCG AGC	1068
Ser Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr Val Ser Ser	
320 325 330 335	
TCT GAC TAC AAA GAC GAA CTT TAAGAATTCT CTAGAGATAT CGTCGACAGA	1119
Ser Asp Tyr Lys Asp Glu Leu	
340	
TCTCTCGAG	1128

## (2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 342 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 64 -

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Lys	Leu	Gly	Thr	Gly	Val	Val	Ser	His	1	5	10	15	
Phe	Asn	Asp	Cys	Pro	Asp	Ser	His	Thr	Gln	Phe	Cys	Phe	His	Gly	Thr	20	25	30		
Cys	Arg	Phe	Leu	Val	Gln	Glu	Asp	Lys	Pro	Ala	Cys	Val	Cys	His	Ser	35	40	45		
Gly	Tyr	Val	Gly	Ala	Arg	Cys	Glu	His	Ala	Asp	Leu	Leu	Ala	Ser	Leu	50	55	60		
Glu	His	His	His	His	His	His	His	Leu	Glu	Gly	Gly	Ser	Leu	Ala	Ala	Leu	65	70	75	80
Thr	Ala	His	Gln	Ala	Cys	His	Leu	Pro	Leu	Glu	Thr	Phe	Thr	Arg	His	85	90	95		
Arg	Gln	Pro	Arg	Gly	Trp	Glu	Gln	Leu	Glu	Gln	Cys	Gly	Tyr	Pro	Val	100	105	110		
Gln	Arg	Leu	Val	Ala	Leu	Tyr	Leu	Ala	Ala	Arg	Leu	Ser	Trp	Asn	Gln	115	120	125		
Val	Asp	Gln	Val	Ile	Arg	Asn	Ala	Leu	Ala	Ser	Pro	Gly	Ser	Gly	Gly	130	135	140		
Asp	Leu	Gly	Glu	Ala	Ile	Arg	Glu	Gln	Pro	Glu	Gln	Ala	Arg	Leu	Ala	145	150	155	160	
Leu	Thr	Leu	Ala	Ala	Ala	Glu	Ser	Glu	Arg	Phe	Val	Arg	Gln	Gly	Thr	165	170	175		
Gly	Asn	Asp	Glu	Ala	Gly	Ala	Ala	Asn	Ala	Asp	Glu	Lys	Leu	Leu	Ser	180	185	190		
Ser	Ile	Glu	Gln	Ala	Cys	Asp	Ile	Cys	Arg	Leu	Lys	Lys	Leu	Lys	Cys	195	200	205		
Ser	Lys	Glu	Lys	Pro	Lys	Cys	Ala	Lys	Cys	Leu	Lys	Asn	Asn	Trp	Glu	210	215	220		
Cys	Arg	Tyr	Ser	Pro	Lys	Thr	Lys	Arg	Ser	Pro	Leu	Thr	Arg	Ala	His	225	230	235	240	
Leu	Thr	Glu	Val	Glu	Ser	Arg	Leu	Glu	Arg	Leu	Glu	Gln	Leu	Phe	Leu	245	250	255		
Leu	Ile	Phe	Pro	Arg	Glu	Asp	Leu	Asp	Met	Ile	Leu	Lys	Met	Asp	Ser	260	265	270		
Leu	Gln	Asp	Ile	Lys	Ala	Leu	Leu	Thr	Gly	Leu	Phe	Val	Gln	Asp	Asn	275	280	285		

- 65 -

Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser Val Glu Thr Asp  
 290 295 300

Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala Thr Ser Ser Ser  
 305 310 315 320

Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr Val Ser Ser Ser  
 325 330 335

Asp Tyr Lys Asp Glu Leu  
 340

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1365 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: pWF46-IL-2

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 1..63

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 64..1329
- (D) OTHER INFORMATION: /product= "IL-2-deltaETA-deltaGAL4"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATGAAAAAGA CAGCTATCGC GATTGCAGTG GCACTGGCTG GTTTCGCTAC CGTTGCGCAA 60

GCT GAC TAC AAG GAC GAC GAT GAC AAG CTG CAC CAT CAT CAC CAT CAC 108  
 Asp Tyr Lys Asp Asp Asp Asp Lys Leu His His His His His His  
 1 5 10 15

AAG CTT GCA CCT ACT TCA AGT TCT ACA AAG AAA ACA CAG CTA CAA CTG 156  
 Lys Leu Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu  
 20 25 30

GAG CAT TTA CTG CTG GAT TTA CAG ATG ATT TTG AAT GGA ATT AAT AAT 204  
 Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn  
 35 40 45

TAC AAG AAT CCC AAA CTC ACC AGG ATG CTC ACA TTT AAG TTT TAC ATG 252

- 66 -

Tyr	Lys	Asn	Pro	Lys	Leu	Thr	Arg	Met	Leu	Thr	Phe	Lys	Phe	Tyr	Met	
		50					55					60				
CCC	AAG	AAG	GCC	ACA	GAA	CTG	AAA	CAT	CTT	CAG	TGT	CTA	GAA	GAA	GAA	300
Pro	Lys	Lys	Ala	Thr	Glu	Leu	Lys	His	Leu	Gln	Cys	Leu	Glu	Glu	Glu	
	65					70				75						
CTC	AAA	CCT	CTG	GAG	GAA	GTG	CTA	AAT	TTA	GCT	CAA	AGC	AAA	AAC	TTT	348
Leu	Lys	Pro	Leu	Glu	Glu	Val	Leu	Asn	Leu	Ala	Gln	Ser	Lys	Asn	Phe	
80				85					90						95	
CAC	TTA	AGA	CCC	AGG	GAC	TTA	ATC	AGC	AAT	ATC	AAC	GTA	ATA	GTT	CTG	396
His	Leu	Arg	Pro	Arg	Asp	Leu	Ile	Ser	Asn	Ile	Asn	Val	Ile	Val	Leu	
			100					105						110		
GAA	CTA	AAG	GGA	TCT	GAA	ACA	ACA	TTC	ATG	TGT	GAA	TAT	GCT	GAT	GAG	444
Glu	Leu	Lys	Gly	Ser	Glu	Thr	Thr	Phe	Met	Cys	Glu	Tyr	Ala	Asp	Glu	
			115					120					125			
ACA	GCA	ACC	ATT	GTA	GAA	TTT	CTG	AAC	AGA	TGG	ATT	ACC	TTT	TGT	CAA	492
Thr	Ala	Thr	Ile	Val	Glu	Phe	Leu	Asn	Arg	Trp	Ile	Thr	Phe	Cys	Gln	
		130					135					140				
AGC	ATC	ATC	TCA	ACA	CTA	ACG	CTA	GAG	GGC	GGC	AGC	CTG	GCC	GCG	CTG	540
Ser	Ile	Ile	Ser	Thr	Leu	Thr	Leu	Glu	Gly	Gly	Ser	Leu	Ala	Ala	Leu	
	145					150					155					
ACC	GCG	CAC	CAG	GCC	TGC	CAC	CTG	CCG	CTG	GAG	ACT	TTC	ACC	CGT	CAT	588
Thr	Ala	His	Gln	Ala	Cys	His	Leu	Pro	Leu	Glu	Thr	Phe	Thr	Arg	His	
160					165					170					175	
CGC	CAG	CCG	CGC	GGC	TGG	GAA	CAA	CTG	GAG	CAG	TGC	GGC	TAT	CCG	GTG	636
Arg	Gln	Pro	Arg	Gly	Trp	Glu	Gln	Leu	Glu	Gln	Cys	Gly	Tyr	Pro	Val	
				180					185					190		
CAG	CGG	CTG	GTC	GCC	CTC	TAC	CTG	GCG	GCG	CGA	CTG	TCA	TGG	AAC	CAG	684
Gln	Arg	Leu	Val	Ala	Leu	Tyr	Leu	Ala	Ala	Arg	Leu	Ser	Trp	Asn	Gln	
			195					200					205			
GTC	GAC	CAG	GTG	ATC	CGC	AAC	GCC	CTG	GCC	AGC	CCC	GGC	AGC	GGC	GGC	732
Val	Asp	Gln	Val	Ile	Arg	Asn	Ala	Leu	Ala	Ser	Pro	Gly	Ser	Gly	Gly	
		210					215					220				
GAC	CTG	GGC	GAA	GCG	ATC	CGC	GAG	CAG	CCG	GAG	CAG	GCC	CGT	CTG	GCC	780
Asp	Leu	Gly	Glu	Ala	Ile	Arg	Glu	Gln	Pro	Glu	Gln	Ala	Arg	Leu	Ala	
	225					230					235					
CTG	ACC	CTG	GCC	GCC	GCC	GAG	AGC	GAG	CGC	TTC	GTC	CGG	CAG	GGC	ACC	828
Leu	Thr	Leu	Ala	Ala	Ala	Glu	Ser	Glu	Arg	Phe	Val	Arg	Gln	Gly	Thr	
240					245					250					255	
GGC	AAC	GAC	GAG	GCC	GCG	GCC	AAC	GCC	GAC	GAG	AAG	CTT	CTG	TCT		876
Gly	Asn	Asp	Glu	Ala	Gly	Ala	Ala	Asn	Ala	Asp	Glu	Lys	Leu	Leu	Ser	
				260				265						270		



- 67 -

TCT ATC GAA CAA GCA TGC GAT ATT TGC CGA CTT AAA AAG CTC AAG TGC	924
Ser Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu Lys Lys Leu Lys Cys	
275 280 285	
TCC AAA GAA AAA CCG AAG TGC GCC AAG TGT CTG AAG AAC AAC TGG GAG	972
Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys Asn Asn Trp Glu	
290 295 300	
TGT CGC TAC TCT CCC AAA ACC AAA AGG TCT CCG CTG ACT AGG GCA CAT	1020
Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu Thr Arg Ala His	
305 310 315	
CTG ACA GAA GTG GAA TCA AGG CTA GAA AGA CTG GAA CAG CTA TTT CTA	1068
Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu Gln Leu Phe Leu	
320 325 330 335	
CTG ATT TTT CCT CGA GAA GAC CTT GAC ATG ATT TTG AAA ATG GAT TCT	1116
Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu Lys Met Asp Ser	
340 345 350	
TTA CAG GAT ATA AAA GCA TTG TTA ACA GGA TTA TTT GTA CAA GAT AAT	1164
Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe Val Gln Asp Asn	
355 360 365	
GTG AAT AAA GAT GCC GTC ACA GAT AGA TTG GCT TCA GTG GAG ACT GAT	1212
Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser Val Glu Thr Asp	
370 375 380	
ATG CCT CTA ACA TTG AGA CAG CAT AGA ATA AGT GCG ACA TCA TCA TCG	1260
Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala Thr Ser Ser Ser	
385 390 395	
GAA GAG AGT AGT AAC AAA GGT CAA AGA CAG TTG ACT GTA TCG AGC TCT	1308
Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr Val Ser Ser Ser	
400 405 410 415	
GAC TAC AAA GAC GAA CTT TAAGAATTCT CTAGAGATAT CGTCGACAGA TCTCTCGAG	1365
Asp Tyr Lys Asp Glu Leu	
420	

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 421 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Lys	Leu	His	His	His	His	His	Lys
1									10					15

- 68 -

Leu Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu  
                   20                  25                  30  
 His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr  
           35                  40                  45  
 Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro  
       50                  55                  60  
 Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu  
       65                  70                  75                  80  
 Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His  
                   85                  90                  95  
 Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu  
           100                  105                  110  
 Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr  
           115                  120                  125  
 Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser  
       130                  135                  140  
 Ile Ile Ser Thr Leu Thr Leu Glu Gly Gly Ser Leu Ala Ala Leu Thr  
       145                  150                  155                  160  
 Ala His Gln Ala Cys His Leu Pro Leu Glu Thr Phe Thr Arg His Arg  
           165                  170                  175  
 Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro Val Gln  
           180                  185                  190  
 Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp Asn Gln Val  
       195                  200                  205  
 Asp Gln Val Ile Arg Asn Ala Leu Ala Ser Pro Gly Ser Gly Gly Asp  
       210                  215                  220  
 Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu Gln Ala Arg Leu Ala Leu  
       225                  230                  235                  240  
 Thr Leu Ala Ala Ala Glu Ser Glu Arg Phe Val Arg Gln Gly Thr Gly  
           245                  250                  255  
 Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp Glu Lys Leu Leu Ser Ser  
           260                  265                  270  
 Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu Lys Lys Leu Lys Cys Ser  
       275                  280                  285  
 Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys Asn Asn Trp Glu Cys  
       290                  295                  300  
 Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu Thr Arg Ala His Leu

- 69 -

305		310		315		320									
Thr	Glu	Val	Glu	Ser	Arg	Leu	Glu	Arg	Leu	Glu	Gln	Leu	Phe	Leu	Leu
				325					330					335	
Ile	Phe	Pro	Arg	Glu	Asp	Leu	Asp	Met	Ile	Leu	Lys	Met	Asp	Ser	Leu
			340					345					350		
Gln	Asp	Ile	Lys	Ala	Leu	Leu	Thr	Gly	Leu	Phe	Val	Gln	Asp	Asn	Val
		355					360					365			
Asn	Lys	Asp	Ala	Val	Thr	Asp	Arg	Leu	Ala	Ser	Val	Glu	Thr	Asp	Met
	370					375					380				
Pro	Leu	Thr	Leu	Arg	Gln	His	Arg	Ile	Ser	Ala	Thr	Ser	Ser	Ser	Glu
	385				390					395					400
Glu	Ser	Ser	Asn	Lys	Gly	Gln	Arg	Gln	Leu	Thr	Val	Ser	Ser	Ser	Asp
			405					410						415	
Tyr	Lys	Asp	Glu	Leu											
			420												

## (2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 41 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CGAGAAGCTT GAGAGCTCTG ACTACAAAGA CGAACTTTAA G

41

## (2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 43 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

AATTCTTAAA GTTCGTCTTT GTAGTCAGAG CTCTCAAGCT TCT

43

- 70 -

## (2) INFORMATION FOR SEQ ID NO: 9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 394 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: pWW 25

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

```
TCTAGAGGGC GGCAGCCTGG CCGCGCTGAC CGCGCACCAG GCCTGCCACC TGCCGCTGGA 60
GACTTTCACC CGTCATCGCC AGCCGCGCGG CTGGGAACAA CTGGAGCAGT GCGGCTATCC 120
GGTGCAGCGG CTGGTCGCCC TCTACCTGGC GGC GCGACTG TCATGGAACC AGGTGACCA 180
GGTGATCCGC AACGCCCTGG CCAGCCCCCG CAGCGGCGGC GACCTGGGCG AAGCGATCCG 240
CGAGCAGCCG GAGCAGGCC GTCTGGCCCT GACCCTGGCC GCCGCCGAGA GCGAGCGCTT 300
CGTCCGGCAG GGCACCGGCA ACGACGAGGC CGGCGCGGCC AACGCCGACG AGAAGCTTGA 360
GAGCTCTGAC TACAAAGACG AACTTTAAGA ATTC 394
```

## (2) INFORMATION FOR SEQ ID NO: 10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

```
CAGATGAAGC TTCTGTCTTC
```

20

## (2) INFORMATION FOR SEQ ID NO: 11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

- 71 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GAATGAGCTC GATACAGTCA ACTG

24

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 443 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vii) IMMEDIATE SOURCE:

(B) CLONE: pWW35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AAGCTTCTGT CTTCTATCGA ACAAGCATGC GATATTTGCC GACTTAAAAA GCTCAAGTGC 60  
TCCAAAGAAA AACCGAAGTG CGCCAAGTGT CTGAAGAACA ACTGGGAGTG TCGCTACTCT 120  
CCCAAAACCA AAAGGTCTCC GCTGACTAGG GCACATCTGA CAGAAGTGGG ATCAAGGCTA 180  
GAAAGACTGG AACAGCTATT TCTACTGATT TTTCCTCGAG AAGACCTTGA CATGATTTTG 240  
AAAATGGATT CTTTACAGGA TATAAAAGCA TTGTTAACAG GATTATTTGT ACAAGATAAT 300  
GTGAATAAAG ATGCCGTCAC AGATAGATTG GCTTCAGTGG AGACTGATAT GCCTCTAACA 360  
TTGAGACAGC ATAGAATAAG TCGGACATCA TCATCGGAAG AGAGTAGTAA CAAAGGTCAA 420  
AGACAGTTGA CTGTATCGAG CTC 443

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 72 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TCACTGGATG GTGGGAAGAT GGA

23

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AGATCCAGGG GCCAGTGGAT AGA

23

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CAAGCTTCTC AGGTACAACT GCAGGAGGTC ACCGTTTCCT CTGGCGG

47

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GAAACGGTGA CCTCCTGCAG TTGTACCTGA GAAGCTTGCA TG

42

- 73 -

## (2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 43 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

TGGCGGTTCT GGTGGCGGTG GCTCCGGCGG TGGCGGTTCT GAC  
43

## (2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 43 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GCCACCGCCG GAGCCACCGC CACCAGAACC GCCACCGCCA GAG  
43

## (2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ATCCAGCTGG AGATCTAGCT GATCAAAGCT  
30

## (2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 43 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

- 74 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

CTAGAGCTTT GATCAGCTAG ATCTCCAGCT GGATGTCAGA ACC

43

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 175 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

AAGCTTGCAT GCAAGCTTCT CAGGTACAAC TGCAGGAGGT CACCGTTTCC TCTGGCGGTG 60

GCGGTTCTGG TGGCGGTGGC TCCGGCGGTG GCGGTTCTGA CATCCAGCTG GAGATCTAGC 120

TGATCAAAGC TCTAGAGGAT CCCCGGTAC CGAGCTCGAA TTCACTGGCC GTCGT 175

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GACATTCAGC TGACCCAG

18

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear



- 75 -

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GCCCGTTAGA TCTCCAATTT TGTCCCCGAG

30

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

ACAAAATTGG AGATCAAAGC TCTAGA

26

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

AGCTTCAGGT ACAACTGCA

19

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

GTTGTACCTG A

11

- 76 -

## (2) INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 48 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

AGCTTGGATC CGGAGGACAG TCCTCCGGAG ACCGGAGGAC AGTCCTCC

48

## (2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 48 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GATCGGAGGA CTGTCCTCCG GTCTCCGGAG GACTGTCCTC CGGATCCA

48

## (2) INFORMATION FOR SEQ ID NO: 29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 40 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GACCCGAAGC TTGGTACCGG TGTGGTGTCC CATTTTAATG

40

## (2) INFORMATION FOR SEQ ID NO: 30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid

- 77 -

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

TTCTGGGAGC TCTCTAGAGA GGCCAGGAGG TCCGC

35

(2) INFORMATION FOR SEQ ID NO: 31:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 173 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

AAGCTTGGTA CCGGTGTGGT GTCCCATTTT AATGACTGCC CAGATTCCCA CACTCAGTTC 60  
TGCTTTCATG GAACCTGCAG GTTTTGGTG CAGGAGGACA AGCCAGCATG TGTCTGCCAT 120  
TCTGGGTACG TTGGTGCACG CTGTGAGCAT GCGGACCTCC TGGCCTCTCT AGA 173

(2) INFORMATION FOR SEQ ID NO: 32:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

TATAATAAGC TTGCACCTAC TTCAAG

26

(2) INFORMATION FOR SEQ ID NO: 33:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- 78 -

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

TTGAATGCTA GCGTTAGTGT TGAGATG

27

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1919 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 64..1908

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

ATGAAAAAGA CAGCTATCGC GATTGCAGTG GCACTGGCTG GTTTCGCTAC CGTTGCGCAA	60
GCT GAC TAC AAG GAC GAC GAT GAC AAG CTG CAC CAT CAT CAC CAT CAC	108
Asp Tyr Lys Asp Asp Asp Asp Lys Leu His His His His His His	
1 5 10 15	
AAG CTT CTG TCT TCT ATC GAA CAA GCA TGC GAT ATT TGC CGA CTT AAA	156
Lys Leu Leu Ser Ser Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu Lys	
20 25 30	
AAG CTC AAG TGC TCC AAA GAA AAA CCG AAG TGC GCC AAG TGT CTG AAG	204
Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys	
35 40 45	
AAC AAC TGG GAG TGT CGC TAC TCT CCC AAA ACC AAA AGG TCT CCG CTG	252
Asn Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu	
50 55 60	
ACT AGG GCA CAT CTG ACA GAA GTG GAA TCA AGG CTA GAA AGA CTG GAA	300
Thr Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu	
65 70 75	
CAG CTA TTT CTA CTG ATT TTT CCT CGA GAA GAC CTT GAC ATG ATT TTG	348
Gln Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu	
80 85 90 95	
AAA ATG GAT TCT TTA CAG GAT ATA AAA GCA TTG TTA ACA GGA TTA TTT	396
Lys Met Asp Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe	
100 105 110	

GTA CAA GAT AAT GTG AAT AAA GAT GCC GTC ACA GAT AGA TTG GCT TCA	444
Val Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser	
115 120 125	
GTG GAG ACT GAT ATG CCT CTA ACA TTG AGA CAG CAT AGA ATA AGT GCG	492
Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala	
130 135 140	
ACA TCA TCA TCG GAA GAG AGT AGT AAC AAA GGT CAA AGA CAG TTG ACT	540
Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr	
145 150 155	
GTA TCG AGC TCG CTA GCA GTA GGT AGC TCA TTG TCA TGC ATC AAC CTG	588
Val Ser Ser Ser Leu Ala Val Gly Ser Ser Leu Ser Cys Ile Asn Leu	
160 165 170 175	
GAT TGG GAT GTT ATC CGT GAT AAA ACT AAA ACT AAG ATC GAA TCT CTG	636
Asp Trp Asp Val Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser Leu	
180 185 190	
AAA GAA CAC GGT CCG ATC AAA AAC AAA ATG AGC GAA AGC CCG AAC AAA	684
Lys Glu His Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys	
195 200 205	
ACT GTA TCT GAA GAA AAA GCT AAA CAG TAC CTG GAA GAA TTC CAC CAG	732
Thr Val Ser Glu Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His Gln	
210 215 220	
ACT GCA CTG GAA CAC CCG GAA CTG TCT GAA CTT AAG ACC GTT ACT GGT	780
Thr Ala Leu Glu His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr Gly	
225 230 235	
ACC AAC CCG GTA TTC GCT GGT GCT AAC TAC GCT GCT TGG GCA GTA AAC	828
Thr Asn Pro Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn	
240 245 250 255	
GTT GCT CAG GTT ATC GAT AGC GAA ACT GCT GAT AAC CTG GAA AAA ACT	876
Val Ala Gln Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr	
260 265 270	
ACC GCG GCT CTG TCT ATC CTG CCG GGT ATC GGT AGC GTA ATG GGC ATC	924
Thr Ala Ala Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile	
275 280 285	
GCA GAC GGC GCC GTT CAC CAC AAC ACT GAA GAA ATC GTT GCA CAG TCT	972
Ala Asp Gly Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser	
290 295 300	
ATC GCT CTG AGC TCT CTG ATG GTT GCT CAG GCC ATC CCG CTG GTA GGT	1020
Ile Ala Leu Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly	
305 310 315	

GAA CTG GTT GAT ATC GGT TTC GCT GCA TAC AAC TTC GTT GAA AGC ATC Glu Leu Val Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser Ile 320 325 330 335	1068
ATC AAC CTG TTC CAG GTT GTT CAC AAC TCT TAC AAC CGC CCG GCT TAC Ile Asn Leu Phe Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala Tyr 340 345 350	1116
TCT CCG GGT GTC GAC GGT ATC GAT AAG CTT CAG GTA CAA CTG CAG CAG Ser Pro Gly Val Asp Gly Ile Asp Lys Leu Gln Val Gln Leu Gln Gln 355 360 365	1164
TCT GGA CCT GAA CTG AAG AAG CCT GGA GAG ACA GTC AAG ATC TCC TGC Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys 370 375 380	1212
AAG GCC TCT GGG TAT CCT TTC ACA AAC TAT GGA ATG AAC TGG GTG AAG Lys Ala Ser Gly Tyr Pro Phe Thr Asn Tyr Gly Met Asn Trp Val Lys 385 390 395	1260
CAG GCT CCA GGA CAG GGT TTA AAG TGG ATG GGC TGG ATT AAC ACC TCC Gln Ala Pro Gly Gln Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Ser 400 405 410 415	1308
ACT GGA GAG TCA ACA TTT GCT GAT GAC TTC AAG GGA CGG TTT GAC TTC Thr Gly Glu Ser Thr Phe Ala Asp Asp Phe Lys Gly Arg Phe Asp Phe 420 425 430	1356
TCT TTG GAA ACC TCT GCC AAC ACT GCC TAT TTG CAG ATC AAC AAC CTC Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr Leu Gln Ile Asn Asn Leu 435 440 445	1404
AAA AGT GAA GAC ATG GCT ACA TAT TTC TGT GCA AGA TGG GAG GTT TAC Lys Ser Glu Asp Met Ala Thr Tyr Phe Cys Ala Arg Trp Glu Val Tyr 450 455 460	1452
CAC GGC TAC GTT CCT TAC TGG GGC CAA GGG ACC ACG GTC ACC GTT TCC His Gly Tyr Val Pro Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 465 470 475	1500
TCT GGC GGT GGC GGT TCT GGT GGC GGT GGC TCC GGC GGT GGC GGT TCT Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser 480 485 490 495	1548
GAC ATC CAG CTG ACC CAG TCT CAC AAA TTC CTG TCC ACT TCA GTA GGA Asp Ile Gln Leu Thr Gln Ser His Lys Phe Leu Ser Thr Ser Val Gly 500 505 510	1596
GAC AGG GTC AGC ATC ACC TGC AAG GCC AGT CAG GAT GTG TAT AAT GCT Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Tyr Asn Ala 515 520 525	1644

- 81 -

GTT GCC TGG TAT CAA CAG AAA CCA GGA CAA TCT CCT AAA CTT CTG ATT	1692
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile	
530 535 540	
TAC TCG GCA TCC TCC CGG TAC ACT GGA GTC CCT TCT CGC TTC ACT GGC	1740
Tyr Ser Ala Ser Ser Arg Tyr Thr Gly Val Pro Ser Arg Phe Thr Gly	
545 550 555	
AGT GGC TCT GGG CCG GAT TTC ACT TTC ACC ATC AGC AGT GTG CAG GCT	1788
Ser Gly Ser Gly Pro Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala	
560 565 570 575	
GAA GAC CTG GCA GTT TAT TTC TGT CAG CAA CAT TTT CGT ACT CCA TTC	1836
Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln His Phe Arg Thr Pro Phe	
580 585 590	
ACG TTC GGC TCG GGG ACA AAA TTG GAG ATC AAA GCT CTA GAG GAT CTC	1884
Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Ala Leu Glu Asp Leu	
595 600 605	
TCG AGT GAG AGA AGA TTT TCA GCC TGATACAGAT T	1919
Ser Ser Glu Arg Arg Phe Ser Ala	
610 615	

## (2) INFORMATION FOR SEQ ID NO: 35:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 615 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Asp Tyr Lys Asp Asp Asp Asp Lys Leu His His His His His His Lys	
1 5 10 15	
Leu Leu Ser Ser Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu Lys Lys	
20 25 30	
Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys Asn	
35 40 45	
Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu Thr	
50 55 60	
Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu Gln	
65 70 75 80	
Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu Lys	
85 90 95	

- 82 -

Met Asp Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe Val  
 100 105 110  
 Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser Val  
 115 120 125  
 Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala Thr  
 130 135 140  
 Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr Val  
 145 150 155 160  
 Ser Ser Ser Leu Ala Val Gly Ser Ser Leu Ser Cys Ile Asn Leu Asp  
 165 170 175  
 Trp Asp Val Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser Leu Lys  
 180 185 190  
 Glu His Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys Thr  
 195 200 205  
 Val Ser Glu Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His Gln Thr  
 210 215 220  
 Ala Leu Glu His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr Gly Thr  
 225 230 235 240  
 Asn Pro Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn Val  
 245 250 255  
 Ala Gln Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Thr  
 260 265 270  
 Ala Ala Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile Ala  
 275 280 285  
 Asp Gly Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser Ile  
 290 295 300  
 Ala Leu Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly Glu  
 305 310 315 320  
 Leu Val Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser Ile Ile  
 325 330 335  
 Asn Leu Phe Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala Tyr Ser  
 340 345 350  
 Pro Gly Val Asp Gly Ile Asp Lys Leu Gln Val Gln Leu Gln Gln Ser  
 355 360 365  
 Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys  
 370 375 380  
 Ala Ser Gly Tyr Pro Phe Thr Asn Tyr Gly Met Asn Trp Val Lys Gln



- 83 -

385		390		395		400									
Ala	Pro	Gly	Gln	Gly	Leu	Lys	Trp	Met	Gly	Trp	Ile	Asn	Thr	Ser	Thr
				405					410					415	
Gly	Glu	Ser	Thr	Phe	Ala	Asp	Asp	Phe	Lys	Gly	Arg	Phe	Asp	Phe	Ser
			420					425					430		
Leu	Glu	Thr	Ser	Ala	Asn	Thr	Ala	Tyr	Leu	Gln	Ile	Asn	Asn	Leu	Lys
			435				440					445			
Ser	Glu	Asp	Met	Ala	Thr	Tyr	Phe	Cys	Ala	Arg	Trp	Glu	Val	Tyr	His
	450					455					460				
Gly	Tyr	Val	Pro	Tyr	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser
465					470					475				480	
Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp
				485					490					495	
Ile	Gln	Leu	Thr	Gln	Ser	His	Lys	Phe	Leu	Ser	Thr	Ser	Val	Gly	Asp
			500					505					510		
Arg	Val	Ser	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asp	Val	Tyr	Asn	Ala	Val
		515					520					525			
Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ser	Pro	Lys	Leu	Leu	Ile	Tyr
	530					535					540				
Ser	Ala	Ser	Ser	Arg	Tyr	Thr	Gly	Val	Pro	Ser	Arg	Phe	Thr	Gly	Ser
545					550					555					560
Gly	Ser	Gly	Pro	Asp	Phe	Thr	Phe	Thr	Ile	Ser	Ser	Val	Gln	Ala	Glu
				565					570					575	
Asp	Leu	Ala	Val	Tyr	Phe	Cys	Gln	Gln	His	Phe	Arg	Thr	Pro	Phe	Thr
			580					585					590		
Phe	Gly	Ser	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Ala	Leu	Glu	Asp	Leu	Ser
		595					600					605			
Ser	Glu	Arg	Arg	Phe	Ser	Ala									
	610					615									

## (2) INFORMATION FOR SEQ ID NO: 36:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1862 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)

- 84 -

## (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1851

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

ATG GAC TAC AAG GAC GAC GAT GAC AAG AAG CTG CAC CAT CAT CAC CAT	48
Met Asp Tyr Lys Asp Asp Asp Asp Lys Lys Leu His His His His His	
1 5 10 15	
CAC AAG CTT CTG TCT TCT ATC GAA CAA GCA TGC GAT ATT TGC CGA CTT	96
His Lys Leu Leu Ser Ser Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu	
20 25 30	
AAA AAG CTC AAG TGC TCC AAA GAA AAA CCG AAG TGC GCC AAG TGT CTG	144
Lys Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu	
35 40 45	
AAG AAC AAC TGG GAG TGT CGC TAC TCT CCC AAA ACC AAA AGG TCT CCG	192
Lys Asn Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro	
50 55 60	
CTG ACT AGG GCA CAT CTG ACA GAA GTG GAA TCA AGG CTA GAA AGA CTG	240
Leu Thr Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu	
65 70 75 80	
GAA CAG CTA TTT CTA CTG ATT TTT CCT CGA GAA GAC CTT GAC ATG ATT	288
Glu Gln Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile	
85 90 95	
TTG AAA ATG GAT TCT TTA CAG GAT ATA AAA GCA TTG TTA ACA GGA TTA	336
Leu Lys Met Asp Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu	
100 105 110	
TTT GTA CAA GAT AAT GTG AAT AAA GAT GCC GTC ACA GAT AGA TTG GCT	384
Phe Val Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala	
115 120 125	
TCA GTG GAG ACT GAT ATG CCT CTA ACA TTG AGA CAG CAT AGA ATA AGT	432
Ser Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser	
130 135 140	
GCG ACA TCA TCA TCG GAA GAG AGT AGT AAC AAA GGT CAA AGA CAG TTG	480
Ala Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu	
145 150 155 160	
ACT GTA TCG AGC TCG CTA GCA GTA GGT AGC TCA TTG TCA TGC ATC AAC	528
Thr Val Ser Ser Ser Leu Ala Val Gly Ser Ser Leu Ser Cys Ile Asn	
165 170 175	
CTG GAT TGG GAT GTT ATC CGT GAT AAA ACT AAA ACT AAG ATC GAA TCT	576
Leu Asp Trp Asp Val Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser	
180 185 190	

CTG AAA GAA CAC GGT CCG ATC AAA AAC AAA ATG AGC GAA AGC CCG AAC Leu Lys Glu His Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn 195 200 205	624
AAA ACT GTA TCT GAA GAA AAA GCT AAA CAG TAC CTG GAA GAA TTC CAC Lys Thr Val Ser Glu Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His 210 215 220	672
CAG ACT GCA CTG GAA CAC CCG GAA CTG TCT GAA CTT AAG ACC GTT ACT Gln Thr Ala Leu Glu His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr 225 230 235 240	720
GGT ACC AAC CCG GTA TTC GCT GGT GCT AAC TAC GCT GCT TGG GCA GTA Gly Thr Asn Pro Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val 245 250 255	768
AAC GTT GCT CAG GTT ATC GAT AGC GAA ACT GCT GAT AAC CTG GAA AAA Asn Val Ala Gln Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys 260 265 270	816
ACT ACC GCG GCT CTG TCT ATC CTG CCG GGT ATC GGT AGC GTA ATG GGC Thr Thr Ala Ala Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly 275 280 285	864
ATC GCA GAC GGC GCC GTT CAC CAC AAC ACT GAA GAA ATC GTT GCA CAG Ile Ala Asp Gly Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln 290 295 300	912
TCT ATC GCT CTG AGC TCT CTG ATG GTT GCT CAG GCC ATC CCG CTG GTA Ser Ile Ala Leu Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val 305 310 315 320	960
GGT GAA CTG GTT GAT ATC GGT TTC GCT GCA TAC AAC TTC GTT GAA AGC Gly Glu Leu Val Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser 325 330 335	1008
ATC ATC AAC CTG TTC CAG GTT GTT CAC AAC TCT TAC AAC CGC CCG GCT Ile Ile Asn Leu Phe Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala 340 345 350	1056
TAC TCT CCG GGT GTC GAC GGT ATC GAT AAG CTT CAG GTA CAA CTG CAG Tyr Ser Pro Gly Val Asp Gly Ile Asp Lys Leu Gln Val Gln Leu Gln 355 360 365	1104
CAG TCT GGA CCT GAA CTG AAG AAG CCT GGA GAG ACA GTC AAG ATC TCC Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser 370 375 380	1152
TGC AAG GCC TCT GGG TAT CCT TTC ACA AAC TAT GGA ATG AAC TGG GTG Cys Lys Ala Ser Gly Tyr Pro Phe Thr Asn Tyr Gly Met Asn Trp Val 385 390 395 400	1200
AAG CAG GCT CCA GGA CAG GGT TTA AAG TGG ATG GGC TGG ATT AAC ACC Lys Gln Ala Pro Gly Gln Gly Leu Lys Trp Met Gly Trp Ile Asn Thr	1248

405								410				415					
TCC Ser	ACT Thr	GGA Gly	GAG Glu 420	TCA Ser	ACA Thr	TTT Phe	GCT Ala	GAT Asp 425	GAC Asp	TTC Phe	AAG Lys	GGA Gly	CGG Arg 430	TTT Phe	GAC Asp	1296	
TTC Phe	TCT Ser	TTG Leu 435	GAA Glu	ACC Thr	TCT Ser	GCC Ala	AAC Asn 440	ACT Thr	GCC Ala	TAT Tyr	TTG Leu	CAG Gln 445	ATC Ile	AAC Asn	AAC Asn	1344	
CTC Leu	AAA Lys 450	AGT Ser	GAA Glu	GAC Asp	ATG Met	GCT Ala 455	ACA Thr	TAT Tyr	TTC Phe	TGT Cys	GCA Ala 460	AGA Arg	TGG Trp	GAG Glu	GTT Val	1392	
TAC Tyr 465	CAC His	GGC Gly	TAC Tyr	GTT Val	CCT Pro 470	TAC Tyr	TGG Trp	GGC Gly	CAA Gln	GGG Gly 475	ACC Thr	ACG Thr	GTC Val	ACC Thr	GTT Val 480	1440	
TCC Ser	TCT Ser	GGC Gly	GGT Gly 485	GGC Gly	GGT Gly	TCT Ser	GGT Gly	GGC Gly 490	GGT Gly	GGC Gly	TCC Ser	GGC Gly	GGT Gly 495	GGC Gly	GGT Gly	1488	
TCT Ser	GAC Asp	ATC Ile	CAG Gln 500	CTG Leu	ACC Thr	CAG Gln	TCT Ser	CAC His 505	AAA Lys	TTC Phe	CTG Leu	TCC Ser	ACT Thr 510	TCA Ser	GTA Val	1536	
GGA Gly	GAC Asp	AGG Arg 515	GTC Val	AGC Ser	ATC Ile	ACC Thr	TGC Cys 520	AAG Lys	GCC Ala	AGT Ser	CAG Gln	GAT Asp 525	GTG Val	TAT Tyr	AAT Asn	1584	
GCT Ala	GTT Val 530	GCC Ala	TGG Trp	TAT Tyr	CAA Gln 535	CAG Gln	AAA Lys	CCA Pro	GGA Gly	CAA Gln 540	TCT Ser	CCT Pro	AAA Lys	CTT Leu	CTG Leu	1632	
ATT Ile 545	TAC Tyr	TCG Ser	GCA Ala	TCC Ser	TCC Ser 550	CGG Arg	TAC Tyr	ACT Thr	GGA Gly	GTC Val 555	CCT Pro	TCT Ser	CGC Arg	TTC Phe	ACT Thr 560	1680	
GGC Gly	AGT Ser	GGC Gly	TCT Ser	GGG Gly 565	CCG Pro	GAT Asp	TTC Phe	ACT Thr 570	TTC Phe	ACC Thr	ATC Ile	AGC Ser	AGT Ser	GTG Val 575	CAG Gln	1728	
GCT Ala	GAA Glu	GAC Asp	CTG Leu 580	GCA Ala	GTT Val	TAT Tyr	TTC Phe	TGT Cys 585	CAG Gln	CAA Gln	CAT His	TTT Phe	CGT Arg 590	ACT Thr	CCA Pro	1776	
TTC Phe	ACG Thr	TTC Phe 595	GGC Gly	TCG Ser	GGG Gly	ACA Thr	AAA Lys 600	TTG Leu	GAG Glu	ATC Ile	AAA Lys	GCT Ala 605	CTA Leu	GAG Glu	GAT Asp	1824	
CTC Leu	TCG Ser 610	AGT Ser	GAG Glu	AGA Arg	AGA Arg	TTT Phe 615	TCA Ser	GCC Ala	TGATACAGAT T							1862	

- 87 -

## (2) INFORMATION FOR SEQ ID NO: 37:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 617 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

```

Met Asp Tyr Lys Asp Asp Asp Asp Lys Lys Leu His His His His His
 1           5           10           15
His Lys Leu Leu Ser Ser Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu
      20           25           30
Lys Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu
      35           40           45
Lys Asn Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro
      50           55           60
Leu Thr Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu
      65           70           75           80
Glu Gln Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile
      85           90           95
Leu Lys Met Asp Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu
      100          105          110
Phe Val Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala
      115          120          125
Ser Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser
      130          135          140
Ala Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu
      145          150          155          160
Thr Val Ser Ser Ser Leu Ala Val Gly Ser Ser Leu Ser Cys Ile Asn
      165          170          175
Leu Asp Trp Asp Val Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser
      180          185          190
Leu Lys Glu His Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn
      195          200          205
Lys Thr Val Ser Glu Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His
      210          215          220

```

- 88 -

Gln Thr Ala Leu Glu His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr  
 225 230 235 240  
 Gly Thr Asn Pro Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val  
 245 250 255  
 Asn Val Ala Gln Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys  
 260 265 270  
 Thr Thr Ala Ala Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly  
 275 280 285  
 Ile Ala Asp Gly Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln  
 290 295 300  
 Ser Ile Ala Leu Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val  
 305 310 315 320  
 Gly Glu Leu Val Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser  
 325 330 335  
 Ile Ile Asn Leu Phe Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala  
 340 345 350  
 Tyr Ser Pro Gly Val Asp Gly Ile Asp Lys Leu Gln Val Gln Leu Gln  
 355 360 365  
 Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser  
 370 375 380  
 Cys Lys Ala Ser Gly Tyr Pro Phe Thr Asn Tyr Gly Met Asn Trp Val  
 385 390 395 400  
 Lys Gln Ala Pro Gly Gln Gly Leu Lys Trp Met Gly Trp Ile Asn Thr  
 405 410 415  
 Ser Thr Gly Glu Ser Thr Phe Ala Asp Asp Phe Lys Gly Arg Phe Asp  
 420 425 430  
 Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr Leu Gln Ile Asn Asn  
 435 440 445  
 Leu Lys Ser Glu Asp Met Ala Thr Tyr Phe Cys Ala Arg Trp Glu Val  
 450 455 460  
 Tyr His Gly Tyr Val Pro Tyr Trp Gly Gln Gly Thr Thr Val Thr Val  
 465 470 475 480  
 Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly  
 485 490 495  
 Ser Asp Ile Gln Leu Thr Gln Ser His Lys Phe Leu Ser Thr Ser Val  
 500 505 510  
 Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Tyr Asn

- 89 -

515	520	525
Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu		
530	535	540
Ile Tyr Ser Ala Ser Ser Arg Tyr Thr Gly Val Pro Ser Arg Phe Thr		
545	550	555
Gly Ser Gly Ser Gly Pro Asp Phe Thr Phe Thr Ile Ser Ser Val Gln		
	565	570
Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln His Phe Arg Thr Pro		
	580	585
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Ala Leu Glu Asp		
	595	600
Leu Ser Ser Glu Arg Arg Phe Ser Ala		
610	615	

## (2) INFORMATION FOR SEQ ID NO: 38:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1605 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 64..1551

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

ATGAAAAAGA CAGCTATCGC GATTGCAGTG GCACTGGCTG GTTTCGCTAC CGTTGCGCAA	60
GCT GAC TAC AAG GAC GAC GAT GAC AAG CTG CAC CAT CAT CAC CAT CAC	108
Asp Tyr Lys Asp Asp Asp Asp Lys Leu His His His His His His	
1 5 10 15	
AAG CTT CTG TCT TCT ATC GAA CAA GCA TGC GAT ATT TGC CGA CTT AAA	156
Lys Leu Leu Ser Ser Ile Glu Gln Ala Cys Asp Ile Cys Arg Leu Lys	
20 25 30	
AAG CTC AAG TGC TCC AAA GAA AAA CCG AAG TGC GCC AAG TGT CTG AAG	204
Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys	
35 40 45	
AAC AAC TGG GAG TGT CGC TAC TCT CCC AAA ACC AAA AGG TCT CCG CTG	252
Asn Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pr Leu	

- 90 -

50	55	60	
ACT AGG GCA CAT CTG ACA GAA GTG GAA TCA AGG CTA GAA AGA CTG GAA Thr Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu 65 70 75			300
CAG CTA TTT CTA CTG ATT TTT CCT CGA GAA GAC CTT GAC ATG ATT TTG Gln Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu 80 85 90 95			348
AAA ATG GAT TCT TTA CAG GAT ATA AAA GCA TTG TTA ACA GGA TTA TTT Lys Met Asp Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe 100 105 110			396
GTA CAA GAT AAT GTG AAT AAA GAT GCC GTC ACA GAT AGA TTG GCT TCA Val Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser 115 120 125			444
GTG GAG ACT GAT ATG CCT CTA ACA TTG AGA CAG CAT AGA ATA AGT GCG Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala 130 135 140			492
ACA TCA TCA TCG GAA GAG AGT AGT AAC AAA GGT CAA AGA CAG TTG ACT Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr 145 150 155			540
GTA TCG AGC TCG CTA GCA GTA GGT AGC TCA TTG TCA TGC ATC AAC CTG Val Ser Ser Ser Leu Ala Val Gly Ser Ser Leu Ser Cys Ile Asn Leu 160 165 170 175			588
GAT TGG GAT GTT ATC CGT GAT AAA ACT AAA ACT AAG ATC GAA TCT CTG Asp Trp Asp Val Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser Leu 180 185 190			636
AAA GAA CAC GGT CCG ATC AAA AAC AAA ATG AGC GAA AGC CCG AAC AAA Lys Glu His Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys 195 200 205			684
ACT GTA TCT GAA GAA AAA GCT AAA CAG TAC CTG GAA GAA TTC CAC CAG Thr Val Ser Glu Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His Gln 210 215 220			732
ACT GCA CTG GAA CAC CCG GAA CTG TCT GAA CTT AAG ACC GTT ACT GGT Thr Ala Leu Glu His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr Gly 225 230 235			780
ACC AAC CCG GTA TTC GCT GGT GCT AAC TAC GCT GCT TGG GCA GTA AAC Thr Asn Pro Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn 240 245 250 255			828
GTT GCT CAG GTT ATC GAT AGC GAA ACT GCT GAT AAC CTG GAA AAA ACT Val Ala Gln Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr 260 265 270			876
ACC GCG GCT CTG TCT ATC CTG CCG GGT ATC GGT AGC GTA ATG GGC ATC			924



- 91 -

Thr	Ala	Ala	Leu	Ser	Ile	Leu	Pro	Gly	Ile	Gly	Ser	Val	Met	Gly	Ile	
			275					280					285			
GCA	GAC	GGC	GCC	GTT	CAC	CAC	AAC	ACT	GAA	GAA	ATC	GTT	GCA	CAG	TCT	972
Ala	Asp	Gly	Ala	Val	His	His	Asn	Thr	Glu	Glu	Ile	Val	Ala	Gln	Ser	
		290					295					300				
ATC	GCT	CTG	AGC	TCT	CTG	ATG	GTT	GCT	CAG	GCC	ATC	CCG	CTG	GTA	GGT	1020
Ile	Ala	Leu	Ser	Ser	Leu	Met	Val	Ala	Gln	Ala	Ile	Pro	Leu	Val	Gly	
	305					310					315					
GAA	CTG	GTT	GAT	ATC	GGT	TTC	GCT	GCA	TAC	AAC	TTC	GTT	GAA	AGC	ATC	1068
Glu	Leu	Val	Asp	Ile	Gly	Phe	Ala	Ala	Tyr	Asn	Phe	Val	Glu	Ser	Ile	
320					325					330					335	
ATC	AAC	CTG	TTC	CAG	GTT	GTT	CAC	AAC	TCT	TAC	AAC	CGC	CCG	GCT	TAC	1116
Ile	Asn	Leu	Phe	Gln	Val	Val	His	Asn	Ser	Tyr	Asn	Arg	Pro	Ala	Tyr	
			340						345					350		
TCT	CCG	GGT	GTC	GAC	GGT	ATC	GAT	AAG	CTT	GAG	CTA	GCA	CCT	ACT	TCA	1164
Ser	Pro	Gly	Val	Asp	Gly	Ile	Asp	Lys	Leu	Glu	Leu	Ala	Pro	Thr	Ser	
		355						360					365			
AGT	TCT	ACA	AAG	AAA	ACA	CAG	CTA	CAA	CTG	GAG	CAT	TTA	CTG	CTG	GAT	1212
Ser	Ser	Thr	Lys	Lys	Thr	Gln	Leu	Gln	Leu	Glu	His	Leu	Leu	Leu	Asp	
		370					375					380				
TTA	CAG	ATG	ATT	TTG	AAT	GGA	ATT	AAT	AAT	TAC	AAG	AAT	CCC	AAA	CTC	1260
Leu	Gln	Met	Ile	Leu	Asn	Gly	Ile	Asn	Asn	Tyr	Lys	Asn	Pro	Lys	Leu	
	385					390					395					
ACC	AGG	ATG	CTC	ACA	TTT	AAG	TTT	TAC	ATG	CCC	AAG	AAG	GCC	ACA	GAA	1308
Thr	Arg	Met	Leu	Thr	Phe	Lys	Phe	Tyr	Met		Lys	Lys	Ala	Thr	Glu	
400					405					410					415	
CTG	AAA	CAT	CTT	CAG	TGT	CTA	GAA	GAA	GAA	CTC	AAA	CCT	CTG	GAG	GAA	1356
Leu	Lys	His	Leu	Gln	Cys	Leu	Glu	Glu	Glu	Leu	Lys	Pro	Leu	Glu	Glu	
			420					425						430		
GTG	CTA	AAT	TTA	GCT	CAA	AGC	AAA	AAC	TTT	CAC	TTA	AGA	CCC	AGG	GAC	1404
Val	Leu	Asn	Leu	Ala	Gln	Ser	Lys	Asn	Phe	His	Leu	Arg	Pro	Arg	Asp	
		435					440						445			
TTA	ATC	AGC	AAT	ATC	AAC	GTA	ATA	GTT	CTG	GAA	CTA	AAG	GGA	TCT	GAA	1452
Leu	Ile	Ser	Asn	Ile	Asn	Val	Ile	Val	Leu	Glu	Leu	Lys	Gly	Ser	Glu	
	450					455						460				
ACA	ACA	TTC	ATG	TGT	GAA	TAT	GCT	GAT	GAG	ACA	GCA	ACC	ATT	GTA	GAA	1500
Thr	Thr	Phe	Met	Cys	Glu	Tyr	Ala	Asp	Glu	Thr	Ala	Thr	Ile	Val	Glu	
	465					470					475					
TTT	CTG	AAC	AGA	TGG	ATT	ACC	TTT	TGT	CAA	AGC	ATC	ATC	TCA	ACA	CTA	1548
Phe	Leu	Asn	Arg	Trp	Ile	Thr	Phe	Cys	Gln	Ser	Ile	Ile	Ser	Thr	Leu	
480					485					490					495	

- 92 -

ACT TAAGAATTCT GGAGATCTCT CGAGTGAGAG AAGATTTTCA GCCTGATACA GATT 1605  
Thr

## (2) INFORMATION FOR SEQ ID NO: 39:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 496 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Lys	Leu	His	His	His	His	His	His	Lys	1	5	10	15
Leu	Leu	Ser	Ser	Ile	Glu	Gln	Ala	Cys	Asp	Ile	Cys	Arg	Leu	Lys	Lys	20	25	30	
Leu	Lys	Cys	Ser	Lys	Glu	Lys	Pro	Lys	Cys	Ala	Lys	Cys	Leu	Lys	Asn	35	40	45	
Asn	Trp	Glu	Cys	Arg	Tyr	Ser	Pro	Lys	Thr	Lys	Arg	Ser	Pro	Leu	Thr	50	55	60	
Arg	Ala	His	Leu	Thr	Glu	Val	Glu	Ser	Arg	Leu	Glu	Arg	Leu	Glu	Gln	65	70	75	80
Leu	Phe	Leu	Leu	Ile	Phe	Pro	Arg	Glu	Asp	Leu	Asp	Met	Ile	Leu	Lys	85	90	95	
Met	Asp	Ser	Leu	Gln	Asp	Ile	Lys	Ala	Leu	Leu	Thr	Gly	Leu	Phe	Val	100	105	110	
Gln	Asp	Asn	Val	Asn	Lys	Asp	Ala	Val	Thr	Asp	Arg	Leu	Ala	Ser	Val	115	120	125	
Glu	Thr	Asp	Met	Pro	Leu	Thr	Leu	Arg	Gln	His	Arg	Ile	Ser	Ala	Thr	130	135	140	
Ser	Ser	Ser	Glu	Glu	Ser	Ser	Asn	Lys	Gly	Gln	Arg	Gln	Leu	Thr	Val	145	150	155	160
Ser	Ser	Ser	Leu	Ala	Val	Gly	Ser	Ser	Leu	Ser	Cys	Ile	Asn	Leu	Asp	165	170	175	
Trp	Asp	Val	Ile	Arg	Asp	Lys	Thr	Lys	Thr	Lys	Ile	Glu	Ser	Leu	Lys	180	185	190	
Glu	His	Gly	Pro	Ile	Lys	Asn	Lys	Met	Ser	Glu	Ser	Pro	Asn	Lys	Thr	195	200	205	

- 93 -

Val Ser Glu Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His Gln Thr  
 210 215 220  
 Ala Leu Glu His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr Gly Thr  
 225 230 235 240  
 Asn Pro Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn Val  
 245 250 255  
 Ala Gln Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Thr  
 260 265 270  
 Ala Ala Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile Ala  
 275 280 285  
 Asp Gly Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser Ile  
 290 295 300  
 Ala Leu Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly Glu  
 305 310 315 320  
 Leu Val Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser Ile Ile  
 325 330 335  
 Asn Leu Phe Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala Tyr Ser  
 340 345 350  
 Pro Gly Val Asp Gly Ile Asp Lys Leu Glu Leu Ala Pro Thr Ser Ser  
 355 360 365  
 Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu  
 370 375 380  
 Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr  
 385 390 395 400  
 Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu  
 405 410 415  
 Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val  
 420 425 430  
 Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu  
 435 440 445  
 Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr  
 450 455 460  
 Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe  
 465 470 475 480  
 Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr L u Thr  
 485 490 495

- 94 -

## (2) INFORMATION FOR SEQ ID NO: 40:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 12 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Glu	Lys	Leu	Glu	Ser	Ser	Asp	Tyr	Lys	Asp	Glu	Leu
1				5					10		

## (2) INFORMATION FOR SEQ ID NO: 41:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

His	His	His	His
1			

## (2) INFORMATION FOR SEQ ID NO: 42:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Ser	Ser	Asp	Tyr	Lys	Asp	Glu	Leu
1				5			

## (2) INFORMATION FOR SEQ ID NO: 43:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

- 95 -

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Gly Gly Gly Gly Ser  
1 5

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

CGGAGGACAG TCCTCCG

17

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Lys Asp Glu Leu  
1

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Arg Glu Asp Leu Lys  
1 5

- 96 -

## (2) INFORMATION FOR SEQ ID NO: 47:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 4 amino acids  
    (B) TYPE: amino acid  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

His Asp Glu Leu  
1

## (2) INFORMATION FOR SEQ ID NO: 48:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 21 amino acids  
    (B) TYPE: amino acid  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala  
1                    5                    10                    15  
Thr Val Ala Gln Ala  
                    20

## (2) INFORMATION FOR SEQ ID NO: 49:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 15 amino acids  
    (B) TYPE: amino acid  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
1                    5                    10                    15

## (2) INFORMATION FOR SEQ ID NO: 50:

- 97 -

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

CGCTAGCTGG TGGTG

15

(2) INFORMATION FOR SEQ ID NO: 51:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

TCGACACCAC CAGCTAGCGA GCT

23

(2) INFORMATION FOR SEQ ID NO: 52:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

CGTGTCAGGC TAGCAGTAGG TAGC

24

(2) INFORMATION FOR SEQ ID NO: 53:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 28 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

CATGCGTGTC GACACCCGGA GAGTAAGC

28

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 53 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

TATGGACTAC AAGGACGACG ATGACAAGAA GCTGCACCAT CATCACCATC ACA

53

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 55 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

AGCTTGTGAT GGTGATGATG GTGCAGCTTC TTGTCATCGT CGTCCTTGTA GTCCA

55



### Patent Claims

1. A multidomain protein comprising, as functional domains, a target cell-specific binding domain, a translocation domain and a nucleic acid binding domain, characterized in that the translocation domain is derivable from diphtheria toxin and does not include that part of said toxin molecule which confers to the cytotoxic effect of the molecule.
2. A multidomain protein comprising, as functional domains, a target cell-specific binding domain, a translocation domain and a nucleic acid binding domain, characterized in that the translocation domain is derivable from bacterial toxins and the target cell-specific binding domain which recognizes a cell surface receptor selected from the group of the EGF receptor-related family of growth factor receptors.
3. A multidomain protein comprising, as functional domains, a target cell-specific binding domain, a translocation domain and a nucleic acid binding domain, characterized in that the translocation domain is derivable from a bacterial toxin and the target cell-specific binding domain recognizes a cell surface receptor on the effector cells of the immune system.
4. A multidomain protein according to claims 1 to 3, characterized in that the translocation domain is derivable from that part of said toxin which mediates internalization of the toxin into the cell.
5. A multidomain protein according to claims 1 to 4, characterized in that the translocation domain is derivable from amino acids 193-378 or 196-384 of diphtheria toxin.
6. A multidomain protein according to claims 1 to 5, characterized in that the target cell-specific binding domain is a single chain antigen binding domain of an antibody.
7. A multidomain protein according to claim 1 comprising as functional domains a target-cell specific binding domain, a translocation domain, a nucleic acid binding domain and, optionally, an endoplasmic reticulum retention signal and a nuclear localisation signal, particularly a protein selected from the group consisting of a protein having the amino acid sequence set forth in SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO:35, SEQ ID NO:37 or SEQ ID NO: 39.

8. A nucleic acid encoding a protein according to claims 1 to 7.
9. A vector comprising a nucleic acid according to claim 8.
10. A protein/nucleic acid complex comprising a multidomain protein according to claims 1 to 7 and an effector nucleic acid to be delivered to a target cell.
11. Use of a complex according to claim 10 for the delivery of a desired nucleic acid to a target cell.
12. A nucleic acid delivery system comprising the complex according to claim 10.
13. Composition for the transfection of eukaryotic cells comprising the complex according to claim 10.
14. Pharmaceutical composition comprising a complex according to claim 10.
15. A complex according to claim 10 for use in the therapeutical or prophylactical treatment of a mammal.
16. Use of a complex according to claim 10 for the preparation of a pharmaceutical composition for the therapeutical or prophylactical treatment of a mammal.
17. A transfection kit comprising a protein according to claims 1 to 7 and an effector nucleic acid to be delivered to a target cell.
18. A method for the delivery of a nucleic acid into a target cell, particularly a higher eukaryotic cell, said method comprising exposing the cells to the complex according to claim 10.
19. A host cell containing a nucleic acid according to claim 8.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 95/04270

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/87 C12N15/62 A61K38/16 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 04696 (MILES INC.) 3 March 1994 see page 6, line 12 - line 36; example 7 ---	1-19
A	DE,C,43 39 922 (MAX-PLANCK-GESELLSCHAFT) 6 October 1994 see the whole document ---	1-19
A	GENE THERAPY, vol. 1, no. 4, July 1994 pages 223-232, S.I.MICHAEL AND D.T.CURIEL 'Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway' cited in the application see the whole document --- -/--	1-19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

29 February 1996

Date of mailing of the international search report

25 MARCH 1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/04270

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO,A,95 28494 (TARGETED GENETICS CORPORATION) 26 October 1995  see examples 7-12  -----</p>	<p>1,3-5,  8-19</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/04270

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11, 18  
because they relate to subject matter not required to be searched by this Authority, namely:  
REMARK: IN SO FAR CLAIMS 11 AND 18 RELATE TO AN IN VIVO OF TREATMENT OF THE HUMAN/ANIMAL BODY THE SEARCH HAS BEEN CARRIED OUT AND BASED ON THE ALLEGED EFFECTS OF THE COMPOSITION.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 95/04270

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9404696	03-03-94	AU-B- 5088593	15-03-94
		CA-A- 2143308	03-03-94
		EP-A- 0658210	21-06-95
		FI-A- 950866	24-04-95
		NO-A- 950726	18-04-95
DE-C-4339922	06-10-94	WO-A- 9506745	09-03-95
WO-A-9528494	26-10-95	AU-B- 2387295	10-11-95